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ABSTRACT

Plasmodium vivax Duffy binding protein (DBP) is an essential ligand for
reticulocyte invasion making it a premier asexual blood stage vaccine candidate.
However, strain-specific immunity due to DBPII allelic variation may complicate
vaccine efficacy, suggesting that an effective DBPII vaccine needs to target
immune responses to conserved epitopes that are potential targets of straintranscending neutralizing immunity. Anti DBPII monoclonal antibodies, which
were previously characterized by COS7 cell binding assay as inhibitory and noninhibitory to DBPII-erythrocyte binding, were mapped to DBPII gene fragment
libraries using phage display. Inhibitory mAb 3C9 binds to a conserved
conformation-dependent epitope in subdomain 3 while non-inhibitory mAb 3D10
binds to a linear epitope in subdomain 1 of DBPII.
More definitive epitope mapping of mAb 3D10 was achieved using a
random peptide library displayed on phage. Since DBP region II is mostly made
up of alpha-helices, we used a randomized helical scaffold library, the Affibody
library, displayed on phage, to determine epitope of conformation-dependent
antibodies.
The immunogenicity of the identified epitopes was evaluated in mice and
the immune sera evaluated for binding to DBPII by ELISA and inhibition of DBPIIerythrocyte binding by the COS7 cell assay. Immune serum from the mAb3C9
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epitope blocked DBPII-erythrocyte, suggesting this epitope could be a good
subunit vaccine target.

	
  

vii

CHAPTER ONE:
INTRODUCTION

WORLDWIDE MALARIA
Malaria, a preventable and curable infectious disease, has plagued
mankind for the centuries and is cumulatively the deadliest disease. The
unmistakable overlap of the prevalence of malaria with certain human
erythrocytic polymorphisms, hemaglobinopathies, enzymopathies and
immunogenetic variants are visible marks of the patterns of selection, where the
homozygote's disadvantage (if any) is balanced by the attenuated virulence of
the malaria parasite to the heterozygote host (Haldane, 1949). The phylum
Apicomplexa of the obligate intracellular parasite, Plasmodium, is known for its
flagship apical organelles (rhoptries, micronemes and dense granules) seen in
the invasive stage. Most species in this phylum simultaneously use three distinct
genomes; housed in the nucleus, mitochondrion and apicoplast (a nonphotosynthetic chloroplast remnant) enabling a complex life cycle as it
effortlessly invades and takes over a myriad of sundry cells. Quinine followed by
Chloroquine, a less toxic derivative, was the drug of choice until resistance was
seen in the 1960’s. Artemisinin in combination with at least one other drug is the
accepted treatment today to prevent speedy development of drug resistance by
the parasite.
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In humans, malaria is caused by P. falciparum, P. vivax, P. malariae, P.
ovale and P. knowlesi; and spread by 70 sub-species of the female Anopheles
mosquito. An estimated 198 million cases of malaria and 584,000 deaths were
left in its wake in 2013. Although the true global burden of the disease is
unknown, due to wide-spread under-reporting, globally, 3.3 billion people, are at
risk of being infected ("World Malaria Report 2014," 2014)

Malaria caused by P. vivax
Plasmodium vivax has the widest geographical distribution and is a major
cause of morbidity (Gething et al., 2012). Although vivax malaria is historically
called ‘benign tertian malaria’, when trying to eliminate malaria it is often the ‘last
parasite standing’ (Garnham, 1951; Tatem et al., 2010).
During the acute vivax malaria stage, paroxysms are accompanied with
headache (87%), cough (42%), muscle pain (35%), nausea (29%), vomiting
(24.5%), abdominal pain (25%), diarrhea (4%), clinical anemia (5%), a palpable
spleen (8%) and palpable liver (3%) (Luxemburger et al., 1998). In recent years
there has been an increase in the number of cases of severe and fatal vivax
malaria in both children and adults particularly with severe anemia and low birth
weight (Genton et al., 2008; Kochar et al., 2005; Lacerda et al., 2012; Rijken et
al., 2012; Tjitra et al., 2008). Strains with low sensitivity to primaquine (the only
drug to prevent relapse) are also increasing (Baird & Hoffman, 2004) along with
widespread resistance to existing antimalarial drugs (Mohan & Maithani, 2010;
Rijken et al., 2011).
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Plasmodium vivax preferentially invades reticulocytes (Butcher, Mitchell, &
Cohen, 1973; Mons, 1990) with Duffy blood group antigen otherwise known as
Duffy antigen receptor for chemokines (DARC) (Miller, Mason, Clyde, &
McGinniss, 1976). DARC, a receptor on the surface of red blood cells (RBCs), is
encoded by the Fy gene with codominant alleles FY*A and FY*B. A point
mutation at the binding site of the transcriptional factor GATA-1 in the Duffy gene
promoter renders the phenotype Duffy antigen negative erythrocytes
(Tournamille, Colin, Cartron, & Le Van Kim, 1995). Interestingly, though the
GATA-1 mutation appears on both alleles, Duffy negative Africans are more likely
to have FY*B while a Duffy negative South East Asian would have FY*A
(Zimmerman et al., 1999). The Fy(a)/Fy(b) phenotype is defined by a nucleotide
transition, giving Gly(Fya) or Asp(Fyb) at position 42 in the extracellular aminoterminal domain (Tournamille, Le Van Kim, Gane, Cartron, & Colin, 1995). FY*A
allele seems to confer some degree of resistance to vivax malaria as compared
to FY*B as antibodies that are either naturally acquired or artificially induced
block rPvDBPII from binding to Fy(a) erythrocyte better than to Fy(b) erythrocytes
(Chittoria, Mohanty, Jaiswal, & Das, 2012; King et al., 2011; Maestre et al., 2010;
Souza-Silva et al., 2014).

MALARIA LIFE CYCLE
Although symptoms of malaria have been described in Chinese literature
dating back to 2700 BC, it was not until 1880 that Charles Louis Alphonse
Laveran “follow(ed) the pigment” and disproved the theory of the day that malaria
	
  

3

was caused by a bacterium. He noticed the parasitic protozoan in the blood of
patients with malaria and that quinine treated them. By 1897, Patrick Manson
and Ronald Ross working together to “follow the flagellum” (in reference to the
male gamete) demonstrated that malaria parasites could be transmitted from
infected patients to mosquitoes which were identified as the definite host.
The life cycle of Plasmodium starts with an infected female Anopheles
mosquito that bites a human for a blood meal and transmits a few sporozoites
from its saliva. These sporozoites invoke an antibody response to sporozoites
proteins. Following the infectious bite, MacCallum (1898) showed that the
parasite travels through the blood to the liver where it develops silently
undergoing clonal expansion for the first 10 days or so in the liver. This is the
exoerythrocytic stage. Within the liver, these sporozoites grow and undergo
several rounds of mitotic division to release tens of thousand merozoites. These
merozoites seem to act as a ‘stealth shuttle’ (Alan F. Cowman & Kappe, 2006) as
it dodges phagocytes like Küpffer cells and dendritic cells and makes its way into
the bloodstream. In P. vivax, sporozoites can differentiate into a dormant stage
called a hypnozoite that, upon activation after months or years, causes clinical
relapse (Krotoski, 1985). Cell-mediated T-cell response is the most important
immune response, destroying infected hepatocytes.
The released merozoites then invade erythrocytes initiating the pathogenic
erythrocytic stage. Inside the erythrocyte, the merozoite grows from a ring form to
a trophozoite, which remains uninucleated. The trophozoite’s nucleus divides
asexually to form schizonts, which further divide to form mononeucleated
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merozoites. When the merozoites are mature, the erythrocyte ruptures releasing
approximately 20 merozoites and some parasitic waste (toxins). These released
merozoites invade new erythrocytes and the cycle of replication and rupture
continues, bringing about the characteristic fever and chills cycle of the disease.
Fever also occurs 2 – 3 days before parasite load is high enough to be detected
in blood. P. vivax has a lower pyrogenic threshold than P. falciparum. Under drug
pressure, sometimes P. falciparum ring-stages can become dormant and hide in
the RBCs until conditions for replication becomes more favorable, although it is
uncertain if the same phenomenon occurs for P. vivax. Naturally acquired
immunity (NAI) is mainly associated with the blood stage of the disease with the
production of antibodies specific to the merozoite proteins. Occasionally, once
immunity to blood-stage is acquired, infections can fall to below limits detectable
by standard microscopic methods, but parasite-infected blood cells are not
completely cleared. When these infections re-emerge to a detectable level, even
causing a clinical episode, it is called recrudescence. These infections are
distinct from relapse infections, which are initiated by new merozoites emerging
from dormant liver stage parasites.
Some merozoites form male or female gametocytes that do not rupture
erythrocytes. In P. vivax, gametocytes develop in 56 hours after infecting a
reticulocyte and can be seen in the blood before the onset of clinical symptoms.
When a female anopheline mosquito feeds on an infected human, it ingests the
parasites in the blood, beginning the sporogonic cycle. In the mosquito,
gametocytes develop into male and female gametes capable of forming a zygote.
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The zygote becomes a motile and elongated oökinate that invades the
mosquito’s midgut wall forming an oocyst. Over several days an oocyst
undergoes 10-11 rounds of mitosis to form a syncytial cell sporoblast that will
release thousands of sporozoites. These sporozoites then migrate to the salivary
gland ready to continue the cycle when the mosquito takes its next blood meal.
Thus the parasite undergoes more than ten stages of cellular differentiation and
invades at least four types of cells within two different hosts.

Immune response to malaria
Historically, malaria immune naïve humans were protected or had a mild
form of the disease after adoptive transfer of serum from an infected human
(Cohen, Mc, & Carrington, 1961; McGregor, 1964). In the mid 1960s,
experiments on neurosyphilitic patients immune naïve to malaria, proved that
immunity to malaria is species and strain specific (Jeffery, 1966). Increased
frequencies of CD4+ T cells and memory CD4+ T cells have been correlated with
protection from P. falciparum and P. vivax infection in humans, respectively
(Jangpatarapongsa et al., 2006; Reece et al., 2004). T cells help produce high
affinity antigen specific B cells, regulate inflammatory response and activate
natural killer (NK) cells and monocytes. High affinity inhibitory antibodies and
memory T cells targeting critical regions of molecules may both be essential for
an effective immune response (Mueller et al., 2013).
The first humoral response is against sporozoites proteins like
circumsporozoite protein (CSP) and thrombospondin related anonymous protein
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(TRAP) (Cerami, Kwakye-Berko, & Nussenzweig, 1992; Hedstrom et al., 1990;
Sultan et al., 1997; Vanderberg, Nussenzweig, & Most, 1969). Several preerythrocytic antigen specific CD4+ and CD8+ T cell epitopes have been identified
(Cockburn et al., 2010; Joshi, Bharadwaj, Chatterjee, & Chauhan, 2000;
Overstreet, Cockburn, Chen, & Zavala, 2008).
Antibodies to merozoite proteins and ligands that are critical for junction
formation and invasion play a crucial role in preventing merozoite invasion of
RBC. In P. falciparum antigenic variation and cytoadherence of infected RBCs,
caused by approximately 60 var genes expressed one at a time that encode for
erythrocyte membrane protein 1 (PfEMP1), is a key contributor to complicated
malaria (Biggs et al., 1991; Roberts et al., 1992; Scherf et al., 1998). While
sequestration enables the parasite to avoid spleen-dependent killing, antigenic
switching is a challenge for antibody production. P. vivax does not have var
genes and because of the flexibility of its host cell it does not need to sequester.
Antibodies also enhance phagocytic activity of monocytes and macrophages.
During the acute phase of the disease, a strong Th1 pro-inflammatory
response is typical for malaria with the production of inflammatory cytokines and
chemokines like tumor necrosis factor (TNF)-alpha, IFN-gamma, IL-1, IL-6, and
IL-12 to help prevent hyperparasitemia (Ockenhouse et al., 2006). Although
inflammatory cytokines help clear parasitemia, it can cause severe disease due
to endothelial dysfunction, sequestration and anemia. Hepcidin, the iron
regulatory hormone secreted from macrophages and hepatocytes, is upregulated in the presence of pro-inflammatory cytokines and may play a key role
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in anemia related complications of P. falciparum infection (Nemeth et al., 2004;
Nweneka, Doherty, Cox, & Prentice, 2010). However, a strong regulatory
response determined by plasma IL-10 levels, have been found to be more
elevated in P. vivax compared to P. falciparum infection (Goncalves, Scopel,
Bastos, & Ferreira, 2012; Han et al., 2010). Antigen-specific CD4+ T cell
expansion is inversely regulated by increase in CD4+(FoxP3+) natural regulatory
T cells (Jangpatarapongsa et al., 2008). CD4+ T cells in turn activate NK and
ϒδT cells (Artavanis-Tsakonas et al., 2003; D'Ombrain et al., 2008), which are
thought to act as a bridge between innate and acquired immunity.
Naturally acquired immunity (NAI), first described by Robert Koch in 1899,
is the collective parasitological and clinical immune response to second and
subsequent infections. NAI is largely associated with antibody response to blood
stage infection but can also result in reduction of transmission of gametes to the
mosquito or interfere with development of gametes in mosquito. NAI is
considered to be cumulatively dependent on exposure to multiple parasitic
infections (premunition), is relatively species and strain specific, and is
modulated by age at first exposure. NAI to P. vivax is manifested as protection
against high-density parasitemia and uncomplicated malaria at a younger age as
compared to P. falciparum (Mueller et al., 2009). Unlike NAI to P. falciparum,
immune naïve adults do no acquire clinical immunity with relatively few
exposures than children (Baird, Jones, et al., 1991; Baird et al., 2003). NAI is one
of the main rationales behind pursuing a multivalent blood stage vaccine.
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MALARIA VACCINES
Vaccination is historically the most effective way to prevent infectious
diseases but the malaria parasite is considerably more complex than bacteria
and viruses that most vaccines target. With over 5000 genes the malaria parasite
is very good at evading the immune system as it uses multiple pathways to
invade host cells with polymorphic stage specific ligands. Hence developing a
vaccine against malaria has intrigued scientists globally across time. The first
success made towards development of a vaccine for malaria was in 1967 using
radiation attenuated sporozoites to protect against infection with malaria in mice
(Nussenzweig, Vanderberg, Most, & Orton, 1967). Today the RTS,S a preerythrocytic, P. falciparum subunit vaccine of the repeat region and Tc epitope of
a CSP, is the only vaccine candidate that has under gone phase 3 clinical trials.
As the efficacy of the vaccine varied greatly with transmission intensity (Bejon et
al., 2013) the need for a more efficacious second-generation anti-infection
vaccine (against pre-erythrocytic stage) and anti-disease vaccine (against
asexual blood stage) is still very urgent. In addition, transmission-blocking
vaccines that target pre-erythrocytic and/or sexual sporogonic stage is also being
studied. Phase I clinical trials for vaccine candidates against P. vivax preerythrocytic stage and for transmission blocking have been carried out (reviewed
in (Reyes-Sandoval & Bachmann, 2013). However, none of the blood stage
vaccine candidates have reached that mile-marker.
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P. vivax asexual blood stage vaccines
Plasmodium vivax merozoite proteins that have a role in reticulocyte
invasion and can elicit a significant NAI are being studied such as the apical
membrane antigen-1 (PvAMA1), merozoite surface proteins (PvMSPs),
reticulocyte binding proteins (PvRBPs) and Duffy binding protein (PvDBP). All of
these proteins except for PvMSPs have highly polymorphic immunodominant
regions that are suggestive of immune pressure. PvMSP1 and PvDBP have
been studied the most.
Though PvRBPs are among the first apically located protein to bind
irreversibly to reticulocytes (Galinski & Barnwell, 1996; Galinski, Medina,
Ingravallo, & Barnwell, 1992), triggering the release of PvDBP from the
mironemes for junction formation (Singh et al., 2005), very few studies have been
done to understand NAI to PvRBPs. One study in Brazil showed antibodies
correlated significantly to exposure and were directed towards the N-terminal
polymorphic putative binding region (Tran et al., 2005).
The apical membrane protein1 is localized in the microneme and AMA1
interacts with rhoptry neck protein-2 (RON2) to form the moving junction complex
during merozoite invasion (Srinivasan et al., 2011). PvAMA1 is pro-inflammatory
and produces an IgG1 and IgG3 response (Wickramarachchi et al., 2006).
Immune response had been detected to linear and conformational epitopes of
the polymorphic Domain II and specifically the conserved loop region (ChesneSeck et al., 2005; Lal et al., 1996; Pizarro et al., 2005).
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The merozoite surface proteins family has several potential vaccine
candidates; PvMSP-1 fragments, PvMSP-3 family (PvMSP-3.1, PvMSP-3.3 and
PvMSP-3.10) PvMSP-4, PvMSP-5 and PvRBP-5 1/2 and PvMSP-9. PvMSP1 is
the most abundant blood stage antigen that undergoes two successive
proteolytic cleavages to form MSP142 and then MSP119 (Blackman, ScottFinnigan, Shai, & Holder, 1994) . Although MSP1 shows humoral and cellular
reactivity; and human antibodies to MSP1 correlated with protection against P.
vivax infection, yet vaccination of non-human primates with MSP119 failed to
consistently induce antibody production (Valderrama-Aguirre et al., 2005). Of the
11-member msp3 gene family, B cell epitopes to PvMSP3.10’s α-helical region
has been reported with a predominance of IgG1 antibodies followed by IgG2
(Lima-Junior et al., 2011). Antibody response to PvMSP9 is high among
individuals that carry HLA-DRB1*04 (Lima-Junior et al., 2010). IgG1 and IgG2
response is correlated with age, IFN-γ and IL-4 responses were also generated
to the peptide (Lima-Junior et al., 2008).

The Duffy Binding Protein
Specific receptor ligand interactions are required for the malaria parasite
to invade erythrocytes. The Duffy binding protein (DBP) was first identified in the
model parasite P. knowlesi (PkDBP) (Adams et al., 1990; Haynes et al., 1988)
and then in P. vivax (PvDBP) (Fang, Kaslow, Adams, & Miller, 1991; Wertheimer
& Barnwell, 1989). The approximately 140 kDa type I membrane DBP is
sequestered in the micronemes and expressed during late schizont development
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and then released on the surface of the merozoite at or around the time of
invasion (Adams et al., 1990; Fang et al., 1991; Haynes et al., 1988; Wertheimer
& Barnwell, 1989).
Unlike P. falciparum, P. vivax merozoites almost exclusively use the Duffy (Fy)
antigen receptor for chemokines (DARC) to invade erythrocytes (Miller et al.,
1976). DARC is a glycosylated membrane protein more abundant on the surface
of reticulocytes than on mature erythrocytes and is also expressed on the
endothelial surfaces of some organs. In vitro invasion studies using P. knowlesi
demonstrated that initial interaction and apical reorientation can take place
normally on most human erythrocytes, but junction does not develop and
invasion does not progress to junction formation on Duffy-negative human
erythrocytes (lack DARC) (Miller et al., 1976). More recently there have been few
P. vivax cases among Duffy negative individuals (Cavasini et al., 2007; Menard
et al., 2013; Ryan et al., 2006) however, these cases seem to be very rare and
an alternate reticulocyte receptor and merozoite ligand has not yet been
identified. Hence DBP is the leading vaccine candidate.
The invasion of erythrocytes by Plasmodium merozoites is a complex,
multistep process involving an initial “long-distance” recognition of red blood cell
surface receptors and attachment, after which a process of reorientation takes
place to align the apical end to face the erythrocyte (Galinski & Barnwell, 1996;
Srinivasan et al., 2011), a tight junction is then formed involving high-affinity
ligand-receptor interactions. The junction is seen initially as a thickening of the
erythrocyte membrane at its point of contact with the merozoite, which then
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transforms into a ring that moves around the merozoite, powered by the
parasite's actin-myosin motor shedding the surface coat in the process. Upon
reaching the posterior pole, the adhesive proteins at the junction are also
proteolytically removed, this time by a resident protease facilitating resealing of
the membrane. When the invasion is complete, the merozoite finds itself in a
vacuole surrounded by a vacuolar membrane called parasitophorous vacuole (A.
F. Cowman & Crabb, 2006).
Although this may not be the only mechanism for invasion of reticulocytes
by P. vivax, PvDBP is the founding member of the family of Duffy-binding-like
erythrocyte binding proteins (DBL-EBPs) (Adams et al., 1992) that includes P.
falciparum EBA175, PfEBL1, P. knowlesi DBPα,β and γ among others (Adams,
Blair, Kaneko, & Peterson, 2001). The Duffy-binding-like domain is characterized
by two cysteine-rich regions (in PvDBP region II and region VI) and conserved
exon-intron structures (Adams et al., 1992).
Growing in vitro P. vivax cultures is a hurdle that is yet to be over come
however, an in vitro functional assay, the COS7-binding assay, was developed to
study binding of RBCs to transfecting COS7 cells expressing DBP on the surface
of COS7 cells. Using the COS7-binding assay it was determined that the
cysteine rich region II of DBP (DBPII) is critical for binding to DARC (Chitnis &
Miller, 1994). However, PvDBPII is extremely polymorphic with a nucleotide
substitution rate four times higher than the rest of the molecule (Ampudia,
Patarroyo, Patarroyo, & Murillo, 1996; J. Cole-Tobian & King, 2003; Xainli,
Adams, & King, 2000). Antibody responses to PvDBP are seen in people living in
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P. vivax endemic areas and the elevated levels of amino acid sequence
polymorphisms may be signs that the molecule is under selective pressure
(Ampudia et al., 1996; J. L. Cole-Tobian et al., 2002; Fraser et al., 1997; P. A.
Michon, Arevalo-Herrera, Fraser, Herrera, & Adams, 1998; Tsuboi et al., 1994).
Using site directed mutagenesis, it was determined that polymorphic
residues flanked residues critical for receptor binding suggesting variation in BC
epitopes is consistent with an immune evasion mechanism (Hans et al., 2005;
VanBuskirk, Sevova, & Adams, 2004). Additional studies confirmed that amino
acid substitutions in some of the polymorphic residues alter sensitivity to antiDBP inhibitory antibodies (VanBuskirk, Cole-Tobian, et al., 2004). In 2011 the
crystal structure of PvDBPII was determined and the structure corroborated
previous studies indicating that polymorphic residues flanked residues critical for
binding, on the surface of PvDBPII (Fig 1.6 A) (Batchelor, Zahm, & Tolia, 2011).
Cumulatively, these results suggest that polymorphic residues act as a
mechanism to misdirect the immune response away from the conserved residues
critical for binding as PvDBPII haplotype-specific antibody response correlates
with only homologous and not heterologous protection (Ceravolo et al., 2009;
Chootong et al., 2010; J. L. Cole-Tobian et al., 2009; Grimberg et al., 2007; King
et al., 2008; VanBuskirk, Cole-Tobian, et al., 2004; Xainli et al., 2002; Xainli et
al., 2003).
PvDBPII is largely alpha-helical and may be assigned into three subdomains delineated by six disulphide bonds. While sub-domain1 of PvDBPII is
made up of an antiparallel beta-hairpin, sub-domains 2 & 3 seen as distinct
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bundles of three alpha-helixes.	
  	
  NMR studies of PvDBPII in contact with the core
region of DARC ectodomain revealed that dimerization of PvDBPII is required for
and driven by receptor engagement as DARC ectodomain form a helix that binds
to the dimer interphase (Fig 1.7 A) (Batchelor et al., 2014). In addition, the
receptor DARC is sulfated at tyrosine residues 30 and 41, right next to residue 42
that expresses the variant Fy(a)/Fy(b) phenotype, and sulfation of tyrosine 41
has been shown to play a critical role in binding to PvDBP (Fig 1.7 B) (Batchelor
et al., 2011; Choe et al., 2005).
Although NAI to PvDBPII is present in P. vivax endemic areas, anti-DBPII
immune response tends to increase with age and exposure (Chootong et al.,
2010; J. L. Cole-Tobian et al., 2002; Grimberg et al., 2007; VanBuskirk, ColeTobian, et al., 2004; Xainli et al., 2003). Studies have shown that about 8-10% of
P. vivax exposed individuals produce high titer strain-transcending broadly
neutralizing antibodies (King et al., 2008), associated with 50% reduction in risk
of infection with P. vivax (Chootong et al., 2010; King et al., 2008). Vaccine
induced anti-DBP antibodies showed partial erythrocyte binding inhibition in
COS7 assay (Devi et al., 2007) as well as partial inhibition of merozoite invasion
of erythrocyte (Arevalo-Herrera et al., 2005). Vaccine induced anti-DBP
antibodies also induced partial protection in monkeys (Arevalo-Herrera et al.,
2005). Crystal structure and site directed mutagenesis studies (Batchelor et al.,
2014; VanBuskirk, Sevova, et al., 2004) suggest that strain transcending
neutralizing antibodies may be directed to the conserved dimer interface (Fig 1.6
B) or may sterically inhibit dimerization.
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In pre-clinical mouse studies, a multi-allele PvDBPII vaccine was more
immunogenic and produced a stronger strain neutralizing response than a singleallele vaccine (Ntumngia et al., 2013). To overcome the inherent tendency for
anti-DBP immune responses to be strain specific, a novel synthetic PvDBPII
called DEKnull was produced. The B-cell immunodominat and polymorphic
residues of the DEK epitope (Chootong et al., 2010) were mutated in DEKnull.
Compared to the natural parent allele Sal1, DEKnull vaccine was less
immunogenic but it produced an immune response that was similar to a single
natural allele vaccine (Ntumngia & Adams, 2012; Ntumngia et al., 2013). These
studies prove that identifying epitope targets of broadly neutralizing inhibitory
antibodies on DBP will be very helpful in designing a vaccine that produces
strain-transcending immunity.

PHAGE DISPLAY AND BIOPANNING
In the mid 1980’s George Smith performed a series of seminal
experiments that revolutionized protein engineering and the study of proteinprotein interactions. Smith demonstrated that a bacteriophage could express an
exogenous protein by genetically encoding the gene (here, gene encoding EcoRI
endonuclease) as a chimera to protein pIII on the surface of the phage, coining
the term phage display (Smith, 1985). These findings meant that proteins could
be easily produced in the right conformation and ready to use on the phage by
cloning the specific gene into the phage genome; which bypassed the laborious
method of producing, selecting, purifying and refolding protein produced within
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bacteria. Smith further demonstrated both, that EcoRI-pIII protein chimera
retained its ability to bind its specific antibody and that phage displaying the
chimera could be selected from a mixture of wild-type phage by affinity
enrichment using anti EcoRI antibodies (Smith, 1985). This method of affinity
enrichment was termed biopanning (Parmley & Smith, 1988).
A bacteriophage (phage) is a virus that exclusively infects bacteria by
attaching to specific bacterial cell wall phage receptors, including sex-pili,
flagella, and cell wall lipoproteins, polysaccharides, and lipopolysaccharides.
Following infection, the phage uses the host’s machinery to synthesize progeny
thereby suppressing the host’s gene expression and metabolic activities. The
lytic cycle of the phage usually culminates in the release of viral progeny and
bacterial cell content into the medium (Neufeld, Mittelman, Buchner, & Rishpon,
2005).
The filamentous phage (Ff) M13, a single-stranded DNA phage that
infects Escherichia coli strain that carries a F- conjugative plasmid, is the most
commonly used phage display vector. Surface protein pIII and VIII have been
used as chimeras with exogenous protein to be expressed. Major capsid protein
VIII has been used to express small peptides in large numbers, to study avidity
interactions, while minor capsid protein pIII can be used to display proteins to
study affinity interactions (Iannolo, Minenkova, Petruzzelli, & Cesareni, 1995;
Smith & Scott, 1993). Gene III protein displayed as 5 copies, at one tip of the
virion, mediates adsorption to the host sex-pili. The C-terminus of the protein III
remains anchored in the phage coat while the N-terminal is responsible for
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binding to the F-pilus of the host. Peptides to be displayed are fused to the Nterminal portion of the gene III protein. To maintain infectivity of the phage, a
special vector system termed 3+3, was developed that included the wild type pIII
gene in a helper phage and the recombinant gene on a phagemid (Bass,
Greene, & Wells, 1990; Russel & Model, 1986).
Over the past three decades phage display has influenced many fields in
the study of malaria like identifying novel protein-protein interactions, drug design
and target validation, diagnostic and therapeutic antibody fragments, vaccine
design and epitope mapping. These are briefly discussed below.
A novel interaction between Erythrocyte binding antigen-181 (EBA-181)
and human erythrocyte membrane protein 4.1 (4.1R) was identified using P.
falciparum cDNA library biopanned against 4.1R (Lanzillotti & Coetzer, 2006;
Sonja B. Lauterbach, Lanzillotti, & Coetzer, 2003). Novel interaction between the
amino-terminus of MSP1 and RBC glycophorin A (GPA) suggesting an essential
role of the MSP1-GPA-band 3 complex during the initial adhesion phase of
malaria parasite invasion of RBCs (Baldwin, Li, Hanada, Liu, & Chishti, 2015).
Novel mosquito midgut receptor, enolase-binding protein (EBP) that binds to
oökinate surface ligand (enolase), is one of the two pathways used by the
oökinates to invade the mosquito midgut. The mosquito EBP was identified when
SM1, a 12-aa peptide mimotope of enolase, identified after 5 rounds of panning
to salivary glands and mosquito midgut was studied (Ghosh, Ribolla, & JacobsLorena, 2001; Vega-Rodriguez et al., 2014). Identification of (novel) enzyme
substrates and inhibitors like P. falciparum M18 aspartyl aminopeptidase
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(PfM18AAP) interaction with the human erythrocyte membrane protein spectrin
are being understood using phage display. PfM18AAP seems to have a
multifunctional role that utilizes several substrates and digests hemoglobin (S. B.
Lauterbach & Coetzer, 2008).
Identifying a possible drug target; a 14-residue long disulfide-bonded
peptide selected by phage display screen targeting the catalytic domain of P.
falciparum serine repeat antigen 5 (SERA5) and delays egress in a dosedependent manner, demonstrating the potential of SERA5 to be targeted by
small molecules (Fairlie et al., 2008). As a possible drug or drug design, peptide
P1 identified from a 7-mere random peptide library was screened against P.
falciparum infected red blood cells (iRBCs) to identify distinctions on the surface
from uninfected erythrocytes. Peptide P1 when conjugated with a peptide having
moderate hemolytic activity showed inhibition of parasite growth (Eda, Eda, &
Sherman, 2004). A 20-aa peptide (R1) identified from a random peptide library
binds to AMA1 and inhibits invasion. During erythrocyte invasion AMA1 binds to
RON2 complex to form the moving junction. Crystal structures of AMA-RON2
and AMA-R1 reveal structural mimicry and will help identify key residues (Harris
et al., 2005; Vulliez-Le Normand et al., 2012).
As a possible diagnostic antibody fragment; two novel binders to P.
falciparum histidine rich protein 2 (rPfHRP2), identified by screening a human
naïve scFv antibody library, have comparable specificities to PfHRP2-specific
mouse mAb C1-13 and is more stable, making it a possible tool for point of care
diagnostics (Leow, Jones, Cheng, Mahler, & McCarthy, 2014). Fab-phage
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display library was made from peripheral blood leukocytes’ mRNA from clinically
immune individuals and biopanned against merozoite surface antigen 3 (MSP-3)
residues 194 to 257. Of the 3 Fab fragments identified one, RAM1, showed
antiparasitic effect (Lundquist et al., 2006).
Subunit vaccine studies have identified a 69-aa peptide F2i that binds to
Glycophorin B on RBC and inhibits binding of erythrocyte-binding ligand-1 (EBL1) on the merozoite. F2i was identified through screening using P. falciparum
cDNA phage display library and purified glycophorin and RBCs (Li et al., 2012).
Transmission blocking vaccine studies on Female Gamete peptide 1 (FGP1) that
binds specifically to the surface of female P. berghei gametes and strongly
reduces P. berghei oocyst formation by interfering with fertilization could be
considered as a transmission blocking vaccine supplementary target (VegaRodriguez, Perez-Barreto, Ruiz-Reyes, & Jacobs-Lorena, 2015). Single-chain Fv
fragments (scFv)-phage display libraries derived from malaria immune patients
was panned against Pfs48/45, a gamete surface protein of the sexual stages of
P. falciparum. Identified human scFv antibodies specific for epitope III of
Pfs48/45 could be used to arrest the sporogenic stages inside the mosquito
(Roeffen et al., 2001).
Epitope mapping of conformation dependent mAb4G2dc1 that binds to P.
falciparum AMA1, critical for erythrocyte invasion (Kocken et al., 1998) was
carried out using phage displayed peptide library identifying three peptides that
bind to 4G2dc1 and mimic an important epitope of AMA1 (Casey et al., 2004;
Sabo et al., 2007). Phage display and crystal structure was also used to map the
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epitope of mAb 45B1 to a conserved region of PyAMA1 which is a region that is
also recognized by inhibitory mAb 4G2 that is specific for PfAMA1 (David L.
Narum, Ogun, Batchelor, & Holder, 2006). Passive immunization with mAb 45B1
specific for P. yoelii AMA1 was protective against a lethal challenge infection with
P. yoelii (D. L. Narum, Ogun, Thomas, & Holder, 2000).
Specifically for DBP, three binding inhibitory single-chain variable
fragment (scFv) antibodies were identified from a library constructed from 3
human patients infected with P. vivax panned on DBPII (Kim et al., 2007).
Antibody surrogates as randomized fragments on diverse scaffold proteins
and designing catalytic antibodies (abzymes) or enzymes with novel specificities
are fields that phage display has not yet been used to analyze and overcome the
various challenges posed by the malarial parasite.

Phage display library
In 1997, Fack and co-workers compared the efficiencies of epitope
mapping using phage display by random peptide phage display libraries and by
gene-fragment libraries in combination with peptide scan. A single round of
panning using the gene-fragment library was enough to affinity select for the
peptides corresponding to the respective epitopes of the mAbs. Random peptide
library however was successful for only two of the mAbs after three to four
rounds of panning (Fack et al., 1997).
In 2001, Coley et al. studied epitope mapping in the malaria antigen,
AMA1. They used a combination of techniques, first the antigen fragments
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identifies the location of the epitopes then random peptide libraries used to
accurately identify amino acids involved in the epitope and finally, phage display
of mutant fragments confirms the role of each residue in the epitope. A panel of
mAbs was generated to obtain binding reagents to the various domains within
the molecule. It was determined that MAb 5G8 recognizes a short linear epitope
within the pro-domain of AMA1 while the epitope recognized by MAb 1F9 is
reduction sensitive and resides in domain-1, within a disulphide-bonded 57
amino acid sub-domain (Coley et al., 2001). This study is worth emulating for P.
vivax DBP.
Epitope mapping using phage display has been mainly focused on the use
of random peptide libraries and gene fragments libraries derived from selected P.
falciparum proteins. This study, aims to use P. vivax DBPII gene fragment
libraries to determine the epitopes of various inhibitory and non-inhibitory mAbs
by biopanning. In addition, a mAb with linear epitope was panned against a
random 20-aa peptide library while antibodies with conformational dependent
epitopes were biopanned against a random helical scaffold, Affibody library.
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estimated 3.3 billion people in 97 countries and territories are at risk of being
infected with malaria and developing disease (Figure 1.1), and 1.2 billion are
at high risk (>1 in 1000 chance of getting malaria in a year). According to
the latest estimates, 198 million cases of malaria occurred globally in 2013
(uncertainty range 124–283 million) and the disease led to 584 000 deaths
(uncertainty range 367 000–755 000), representing a decrease in malaria
case incidence and mortality rates of 30% and 47% since 2000, respectively.
The burden is heaviest in the WHO African Region, where an estimated 90%
of all malaria deaths occur, and in children aged under 5 years, who account
for 78% of all deaths.

TABLES AND FIGURES

Figure 1.1 Countries with ongoing transmission of malaria, 2013
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Review: Recent advances in malaria vaccine development
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of infection, to provide protection in the case of
encountering the disease-causing agent again.
Malaria vaccine development is an active research
area with enormous challenges. As the parasite
proceeds from a sporozoite through the liver stage
to the replicating cycle of the blood stage, it
undergoes morphological changes and displays
antigenic variations. This allows the parasite to
evade the protective immune responses of the host.
As a result, the acquisition of long-term sterile
immunity, which is often associated with recovery
from many other infectious diseases, is not
observed in malaria-infected individuals. Despite
these difficulties, the most convincing evidence

midgut to form a zygote and subsequently a motile
ookinete. Okinetes penetrate the midgut epithelial
cells and rest between the midgut epithelium and
the basal lamina to form oocysts. The oocysts
undergo a complex asexual development stage,
which eventually generates infective sporozoites
that can be introduced into the human host at the
next blood meal via the mosquito saliva, thereby
ensuring the continuation of the parasite life cycle.
Vaccines against malaria
The purpose of vaccination strategies is to induce
protective memory immune responses in advance
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Red Blood Cell Polymorphism and Susceptibility to Plasmodium vivax
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Figure 2.8 Overview of P. vivax merozoite interaction with the human red blood
cell. Initial attachment occurs between any part of the merozoite (blue) and erythThe merozoite
reorients,
positioning(Zimmerman,
its apical end for
attachment
to &
Figurerocyte
1.4: (red).
Merozoite
Invasion
of Erythrocytes
Ferreira,
Howes,
the
red
cell
membrane.
A
junction
forms
between
the
apical
end
of
the
merozoMercereau-Puijalon, 2013) ADVANCES IN PARASITOLOGY by ACADEMIC
ite and the erythrocyte membrane of Duffy-positive cells (first call-out box). In
PRESS. Reproduced with permission of ACADEMIC PRESS
contrast, P. knowlesi electron microscopy has shown thin filaments between the
merozoite apical end and the Duffy-negative red cell membrane; however, the
merozoite is not drawn into contact with the red cell and the junction fails to form.
This has implied that junction formation fails to occur between P. vivax and the
Duffy-negative red cell membrane as well (second call-out box). Once a durable
junction has formed between the merozoite and the red cell, micronemes (green)
and rhopteries (dark blue) release their contents, the red cell membrane invaginates and the merozoite moves into the parasitophorous vacuole (third call-out
box). Movement of the gliding junction is complete once the merozoite is engulfed
within the parasitophorous vacuole and the orifice at the red cell membrane is
sealed (fourth call-out box). (For interpretation of the references to colour in this
figure legend, the reader is referred to the online version of this book.)
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AR2CSA DBL6E revealed a dimeric organization identical to the RII-PvDBPcurrently
dimer.unidentified
Criticalmechanisms.
VAR2CSA DBL6E binding residues are shown in red
The crystallographic and ITC solution studies presented here
re 4 RII-PvDBP’s dimer interface and receptor binding site are conserved insupport
VAR2CSA
DBL6E.
(a) Examination
of the crystal packing interfaces
a step-wise
binding model
in which receptor-induced

a

DBP-RII dimerization facilitates formation of a heterotrimer that
subsequently recruits a second DARC molecule to form a
heterotetramer (Fig. 8). Due to avidity contributions to binding
inherent in a two-site mechanism, this heterotetrameric complex
may enable theDARC-binding
observed tight binding
grooveof P. vivax to the RBC
membrane. Since recombinant DBP-RII is monomeric in the
absence of DARC when examined in solution [26], the dimer
interface and DARC binding pockets are exposed and accessible
to antibodies prior to DARC engagement. DARC is known to
exist as a homodimeric and heterodimeric GPCR [36]. The Lys2392
heterotrimer and heterotetramer could represent DBP-RII binding to a DARC heterodimer or homodimer, respectively. The
observed transitions may be a selectivity mechanism for DBP-RII
to preferentially bind homodimeric DARC while maintaining the
ability to bind to a DARC heterodimer. The binding model
proposed here is applicable to other DBL domain proteins that
RII-PvDBP
may oligomerize upon
receptor binding [9,26,37–39]. Since
dimerization is prevalent in receptor signaling, it is plausible that
complex assembly initiates a signal through the transmembrane
and cytoplasmic domains of DBP to activate pathways of invasion.
Although structure determination of the DBP-RII:DARC
complexes allows for visualization and identification of critical
contact points, the relevance of each intermediate to complex
assembly in solution is not immediately known from the static
pictures of binding. To begin to assess the biological role of
complex assembly, we utilized ITC to demonstrate that two
binding events corresponding to the formation of a heterotrimer
and heterotetramer exist in solution. We further tested mutant
DBP-RII constructs for RBC binding and demonstrated that these
mutations ablate binding to RBCs, supporting the biological role
of the DARC contacts identified here as well as the role of the
dimer interface. In addition, the large buried surface area for both
DARC binding sites and the ITC measurements suggest high
affinity interactions. This study thus unambiguously identifies
DARC residues 19–30 as a critical binding element that interacts
with DBP residues L270-K289, Q356-K367 and F261-T266.
The biphasic profile obtained by ITC is different from studies
previously reported where a single binding event with a molar
ratio of 1 was observed indicative of the heterotetramer [26]. This
difference is likely due to the buffer conditions used in each case.
In prior studies, titrations were performed at a salt concentration
of 50 mM while the studies presented here were performed in PBS
to examine binding under physiological conditions. These results
suggest that observation of the heterotrimer intermediary step by
ITC is salt dependent. Never-the-less, the biphasic profile and step
wise binding mechanism presented here are representative of the
assembly mechanism under physiologically relevant conditions.

CSPG binding site
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Figure 1.7: ‘DEK’ epitope and putative sulfotyrosine-binding pocket on PvDBPII
crystal structure (Batchelor et al., 2014; Batchelor et al., 2011). DBPII monomers
are colored green and yellow (A) DBPII:DARC heterotetramer with DACR
ectodomain helical monomers in pink and purple. Polymorphic residues in blue
and the most polymorphic region called the ‘DEK’ epitope, (B) Putative
sulfotyrosine-binding pocket in red. Reprinted by permission from Macmillan
Publishers Ltd: Nature Structural & Molecular Biology (Batchelor et al., 2011),
copyright (2011)
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CHAPTER TWO:
DEFINING THE IMMUNOREACTIVE SURFACE OF PLASMODIUM VIVAX
DUFFY BINDING PROTEIN REGION II

ABSTRACT
Plasmodium vivax Duffy binding protein region II (DBPII) is an essential
ligand for reticulocyte invasion, thereby making this molecule an attractive
vaccine candidate against asexual blood-stage P. vivax. However, strain-specific
immunity due to DBPII allelic variation may complicate vaccine efficacy,
suggesting that an effective DBPII vaccine needs to target immune response to
conserved epitopes that are potential targets of strain-transcending neutralizing
immunity. Anti DBPII mAbs, which were previously functionally characterized by
in vitro COS7 cell binding assay as inhibitory and non-inhibitory to DBPIIerythrocyte binding, were mapped to DBPII gene fragment libraries using phage
display. Inhibitory mAb 3C9 binds to a conserved conformation-dependent
epitope in subdomain 3 while non-inhibitory mAb 3D10 binds to a linear epitope
in subdomain 1 of DBPII. In addition, more definitive epitope mapping of mAb
3D10 was achieved using a random peptide library displayed on phage. To
determine the potential of these minimal peptide epitopes to function as an
epitope-specific vaccine, their immunogenicity to induce functionally inhibitory
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antibodies were evaluated. The mAb 3C9 epitope elicited antibodies that
inhibited DBP binding to erythrocytes whereas mAb 3D10 epitope did not.

INTRODUCTION
Plasmodium vivax is the second most prevalent cause of human malaria
and is globally the most widely distributed leaving about 40% of the world’s
population at risk (Gething et al., 2012). Although vivax malaria is historically
called ‘benign tertian malaria’ (Garnham, 1951) there have been increasing
reports of clinical severity with emerging virulent forms of the parasite (Alexandre
et al., 2010; Kochar et al., 2009), recurrent clinical episodes due to reactivation of
the dormant forms in the liver (Krotoski et al., 1982) and widespread drug
resistance (Baird, Basri, et al., 1991; Price et al., 2014; Rieckmann, Davis, &
Hutton, 1989) (Baird, Basri, et al., 1991; Price et al., 2014; Rieckmann et al.,
1989), which potentially includes strains with low sensitivity to primaquine, the
only drug against relapse, or in people with a poor ability to metabolize the drug
to its active form (Baird & Hoffman, 2004; Bennett et al., 2013; Pybus et al.,
2013). There is an urgent need to develop new therapies, especially a vaccine to
control and prevent vivax malaria. Immunity to asexual blood stage antigens is
especially to those that play a role in merozoite invasion of erythrocyte.
Merozoite antigens are believed to be an important component of naturally
acquired immunity to malaria (Marsh & Kinyanjui, 2006; Yazdani, Mukherjee,
Chauhan, & Chitnis, 2006), and represents ideal candidates for vaccine
mediated-immunity against blood stage infection (Mueller et al., 2013).
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Plasmodium vivax Duffy binding protein (PvDBP) binds to its cognate receptor
Duffy antigen receptor for chemokines (DARC) on reticulocytes forming an
irreversible junction, critical for merozoite invasion (Adams et al., 1990; Adams et
al., 1992; Chitnis, Chaudhuri, Horuk, Pogo, & Miller, 1996; Miller et al., 1976;
Miller, Mason, Dvorak, McGinniss, & Rothman, 1975; Wertheimer & Barnwell,
1989). In most circumstances P. vivax merozoites almost exclusively use DARC
as a receptor to invade reticulocytes (Miller et al., 1976). However, more recently,
there have been a few P. vivax cases reported among Duffy negative individuals
(Cavasini et al., 2007; Menard et al., 2013; Ryan et al., 2006), although an
alternate receptor-ligand invasion pathway is unknown. Hence PvDBP remains a
prime candidate for vaccine-induced immunity against blood stage P. vivax
infection.
Plasmodium vivax DBP is a type I membrane protein localized to the
merozoite micronemes and is a member of the Duffy binding-like erythrocytebinding proteins (DBL-EBP) family characterized by two conserved cysteine rich
domains (Adams et al., 1990; Adams et al., 1992) The DBL-EBP and share
similar molecular structures and functional characteristics (Adams et al., 2001;
Adams et al., 1990; Adams et al., 1992; Mayer, Kaneko, Hudson-Taylor, Reid, &
Miller, 2001; D. L. Narum, Fuhrmann, Luu, & Sim, 2002). A 330 amino acid
region within the extracellular portion of DBP, also known as DBP region II
(DBPII) constitutes the principal determinants for receptor recognition (Adams et
al., 1992; Chitnis & Miller, 1994; Ranjan & Chitnis, 1999; VanBuskirk, Sevova, et
al., 2004). The central region of DBPII is highly polymorphic (Ampudia et al.,
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1996; Tsuboi et al., 1994; Xainli et al., 2000), in a pattern consistent with high
immune selection pressure on DBPII (Baum, Thomas, & Conway, 2003; Baum,
Ward, & Conway, 2002). Residues critical for receptor recognition are flanked by
polymorphic residues that are not important for binding to the receptor (Batchelor
et al., 2011; VanBuskirk, Sevova, et al., 2004; Xainli et al., 2000). These
polymorphisms represent a potential challenge to developing a vaccine since
they contribute to strain-specificity in naturally-acquired immunity (J. L. ColeTobian et al., 2009; McHenry, Barnes, Ntumngia, King, & Adams, 2011;
Ntumngia et al., 2012b; VanBuskirk, Cole-Tobian, et al., 2004).
In endemic regions, individuals develop anti-DBPII antibodies, which
increase with age, suggesting a boosting effect from repeated exposure to
infection (King et al., 2008; P. Michon, Fraser, & Adams, 2000). Furthermore,
anti-DBP antibodies tend to be weak, short-lived and strain-specific (Ceravolo et
al., 2009; King et al., 2008; Xainli et al., 2003) with allelic differences appearing
to be driven by immune selection (McHenry et al., 2011; VanBuskirk, ColeTobian, et al., 2004). Few individuals develop high titers of broadly reactive,
invasion-inhibitory anti-DBPII antibodies (Chootong et al., 2010; J. L. ColeTobian et al., 2009; King et al., 2008). These data are all consistent with the
hypothesis that variation is an immune evasion mechanism responsible for
strain-specific immunity and that stable, broadly inhibitory immunity is achieved
when antibodies target functionally conserved epitopes.
Phage display has been a useful tool for epitope mapping with the
advantages of rapidly producing refolded protein, fused to phage coat; forming a
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traceable link back to the genotype (Smith, 1985; Wilson & Finlay, 1998). In
malaria, phage display has been used to map epitopes on apical membrane
antigen 1 (AMA1) (Casey et al., 2004; Coley et al., 2001; David L. Narum et al.,
2006; Sabo et al., 2007), merozoite surface protein (MSP) (Demangel, Lafaye, &
Mazie, 1996) and circumsporozoite protein (CSP) (Greenwood, Willis, & Perham,
1991; Monette, Opella, Greenwood, Willis, & Perham, 2001; Willis, Perham, &
Wraith, 1993). These studies have used a combination of phage display of
random peptide libraries, gene fragment libraries, crystal structure studies along
with peptide immunizations to determine mimotopes and eventually epitopes on
these antigens.
Previously, we generated and immunologically characterized a panel of
anti-DBPII murine mAbs. Some of these monoclonal antibodies were broadly
inhibitory like mAbs 3C9, 2D10, 2C6 and 2H2 while mAb 3D10 was highly
reactive but still a poor inhibitor to DBPII-erythrocyte binding in a standard in vitro
COS 7 cell assay (Ntumngia et al., 2012b). With the exception of mAb 3D10, all
the mAbs specifically recognized only conformational dependent epitopes on
recombinant DBPII. Crystallography studies reveal that DBPII is largely alphahelical and may be assigned into three sub-domains delineated by six disulphide
bonds (Batchelor et al., 2011). Using phage display we have previously shown
that, each of the sub-domains or natural combinations of the sub-domains of
DBPII have varying patterns of affinity to these mAbs (Siddiqui et al., 2012).
These data suggest that identifying the epitopes of these inhibitory and noninhibitory mAbs will help design a strain-transcending subunit vaccine.
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In this study, we further map the epitopes of these anti-DBPII mAbs by
screening DBPII gene fragment libraries expressed on M13 phage surface for
minimal reactive peptide fragments. DBPII epitopes identified for the broadly
inhibitory anti-DBPII mAb 3C9 and non-inhibitory mAb 3D10, conjugated to
carrier protein KLH, were used to produce an antibody immune response in
BLAB/c mice. Anti-3C9 epitope but not anti-3D10 epitope antibodies inhibited
DBPII-erythrocyte binding. Site directed mutagenesis was further carried out to
determine essential residues within the epitope. The information derived from this
study contributes to our understanding of the specific targets for vaccine-elicited
protective immunity. In particular, this study demonstrates an approach that may
be successful in boosting antibody responses targeted against conserved
protective epitopes, with functional inhibition against broader allelic variants and
diverse P. vivax strains.

MATERIALS AND METHODS

Generation of phage displayed DBPII gene fragment libraries
The full-length PCR product (20 µg) from DBPII Sal1 and 7.18 haplotypes
were digested with DNase I at 5 U/ml. The resulting fragments were purified by
sodium acetate precipitation and ragged ends blunted with a Vent polymerase
(NEB). The pHENH6 vector was digested with PstI (NEB) and also blunted with
Vent polymerase. The resulting products from the randomly fragmented DBPII
were cloned into the treated pHEN-H6 vector and then into TG1 E. coli by
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electroporation. The distribution of the fragments in the library was determined by
PCR and sequencing of forty random clones. The distribution of the fragments in
the library were determined by PCR and sequencing of forty random clones. The
library was then grown in 20mls of 2xTryptone-yeast extract media containing 50
µg/ml of ampicillin at 37°C, shaking until OD 600 nm. 1x1011PFU of M13K07
helper phage was added and cultured for an extra 1 h at 37°C without shaking to
allow infection. The entire culture was then transferred into 400 ml of super broth,
containing 70 µg/ml kanamycin and 50 µg/ml ampicillin, and incubated at 37°C
with shaking overnight. The bacteria was pelleted by centrifugation at 8,000 X g
for 15 min and the phage precipitated from the supernatant with PEG-NaCl as
described (Adda, Tilley, Anders, & Foley, 1999; Coley et al., 2006). The phage
was resuspended in 1 ml of PBS and used subsequently or stored at -80°C.

Panning of phage displayed DBPII gene fragment library
Affinity panning of DBPII Sal1 gene fragment to anti-DBPII mAbs 3D10,
3C9, 2D10, 2C6 and 2D10 was carried out as described previously (Coley et al.,
2001). Briefly, 10 wells of Maxisorp-Nunc ELISA plate were coated over night at
4°C with 100 µl per well of test mAb at a final concentration of 2.5 µg/ml diluted in
PBS. Plates were washed twice with PBS and unbound surfaces blocked with
200 µl of 5% skimmed milk in PBS for 2 h at room temperature. After another
round of washing, approximately 1x1011 phage/ well in 1% skimmed milk in PBS
were added to wells and incubated for 1 h at room temperature. Non-adherent
phage particles were washed off twice with PBS/0.05% Tween-20. The bound
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phage was eluted with 100 µl of 0.1M Glycine, pH 2.2 and immediately added to
10 ml of log phase E. coli TG1 cells and cultured for 30 mins at 37°C for infection
to occur. Ampicillin was added to 50 µg/ml and the culture and incubated for
another 30 mins at 37°C before addition of the M13 helper phage and then
incubated for another 1 h at 37°C. The culture was then transferred to a 200 ml
super broth containing 50 µg/ml of ampicillin and 70 µg/ml of kanamycin and
incubated at 37°C overnight with shaking at 200 rpm. The phage was harvested
as described above and another round of panning carried out for a total of up to
four panning cycles per antibody. Ten clones from each round of panning were
selected, their inserts amplified by PCR and sequenced to determine the identity
of the fragments of DBPII that binds to each mAb.

Panning a random peptide library on mAb-3D10
Panning on mAb 3D10 was performed using a random 20mer peptide
library (Courtesy of Foley M and Anders RF, La Trobe University, Australia) as
described (Adda et al., 1999; Coley et al., 2001). Briefly, phage peptide library at
1011 phage/well was incubated with mAb 3D10 coated wells for 1 h at room
temperature. Eluted phage was allowed to re-infect K91 E. coli grown to log
phase in 10 ml Tryptone-yeast extract media at 37°C for 1 h and then grown
overnight in 200 mls of super broth with 40 µg/ml of tetracycline. Phage was
harvested and further rounds of panning carried out as described above. Clones
isolated from round 3 were sequenced to determine the peptide sequences.
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ELISA of phage displayed rounds of panning
Enrichment ELISA was performed as described (Coley et al., 2001).
Briefly, 100 µl of anti-DBP mAbs antibodies at 2.5 µg/ml in PBS were coated on
to wells of 96-well microtiter plates (Maxisorp-Nunc) overnight at 4°C. AntiPfAMA1 specific, mAb-1F9 or 5G8 (Coley et al., 2001) was coated on each plate
as negative control antibody. The plates were washed twice with PBS
0.05%Tween-20 and blocked for 2 h at room temperature with 200 µl/well of 10%
skimmed milk diluted in wash buffer. After three washes, phage diluted in
PBS/1% milk to 1x1011 pfu/ml was added in triplicates and incubated for 2 hours
at room temperature. Plates were washed four times and the wells were
incubated with HRP-conjugated anti-M13 mAb (GE Life Sciences) for 1 h at room
temperature. The plates were then washed five times and bound phage detected
by incubating wells with 100 µl of H2O2 activated TMB substrate (Sigma). The
reaction was stopped with 100 µl 2 N H2SO4 and plates were read at 450 nm
absorbance.

Immunoblots
Approximately 1X1012 phage particles were boiled in SDS-PAGE sample
buffer for 3 min and separated by SDS-PAGE and electrophoretically transferred
on to nitrocellulose membrane. The membrane was blocked overnight in 10%
skimmed milk diluted in PBS/Tween-20. The membrane was probed with antiDBPII mAb, washed with PBS/Tween-20 before incubating with an HRP-
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conjugated anti-mouse secondary antibody. The bound antibody was detected by
enhanced chemiluminescence (ECL) substrate (Amersham).

Immunizations
Peptides corresponding to sequences of the epitopes identified from
panning on the gene fragment library and mimotopes from panning on the
random peptide were synthesized and conjugated to keyhole limpet hemocyanin
(KLH) using Maleimide-Activated mcKLH (ThermoScientific 77611) according to
the manufacturer’s specifications. The following 6 peptides were produced
commercially (Pacific Immunology): 3C9 epitope peptide (3C9-e1) from DBPII
sub-domain 3; 3D10 epitope peptide (3D10-e1) from DBPII sub-domain 1; 3D10
mimotope 1; (3D10-m1) ; 3D10 mimotope 2: (3D1-m2); 3D10 mimotope 3:
(3D10-m3) and a control peptide.
The conjugated peptides were used to immunize 6-8wks old Balb/c mice
(Harlan) to raise immune sera. All animals were handled in compliance with
approved IACUC protocol and good animal practice. Briefly, mice in all groups,
(n=10) were bled for pre-immune sera and each immunized thrice at three week
intervals with 5 µg of peptide conjugated to KLH emulsified in Titermax Gold
adjuvant. Each animal received a 50 µl antigen-adjuvant mix administered
subcutaneously at the base of the tail. Mice immunized with KLH and adjuvant
alone served as control. All mice were bled for final serum four weeks after the
second boost.
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Measurement of antibody titers
Total anti-peptide IgG titers in the serum of each group was evaluated by
end point titration ELISA against and to recombinant DBPII Sal1 and peptide
conjugated to bovine serum albumin (BSA). Imject™ Maleimide-Activated BSA
Spin Kit (ThermoScientific 77667) was used as specified by manufacturer to
conjugate the peptides. ELISAs were carried out as described previously
(Ntumngia et al., 2012b), 0.1 µg of peptide conjugated to BSA or 0.25 µg of
recombinant antigen were coated per well of a microtiter plate over night and
blocked with 5% skimmed milk PBS/0.05% Tween 20 detected by 3-fold dilution
of mouse sera was used starting at 1:200. Bound antibodies were detected using
alkaline phosphatase-conjugated anti-mouse antibody (Kirkegaard & Perry
Laboratories). Pre-immune serum, at the lowest dilution, served as background
and was subtracted.

Measurement of functional inhibition of DBP-Erythrocyte binding
Pooled immune serum from each group of mice that recognized rDBPII
Sal1 by ELISA was tested further for inhibition of DBPII-erythrocyte binding by a
modified version of the standard in vitro COS7 cell assay (Chitnis & Miller, 1994;
P. Michon et al., 2000). A panel of naturally occurring DBPII alleles were
transiently expressed on the surface of transfected COS7 cells as previously
described (Ntumngia et al., 2013). Cells were pre-incubated with triple-fold
dilution (starting at 1:50) of pooled group sera 42 h post transfection, followed by
incubation with human Duffy positive erythrocytes. Inhibition of binding by each
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serum was calculated as a percentage of Duffy positive erythrocyte binding in
immune versus corresponding pre-immune serum control incubated on every
plate (Ntumngia et al., 2013).

Immunofluorescence assay of COS7-surface expressed DBPII
A few DBPII constructs with single and multiple residue mutations, in
epitope residues, were produced (GenScript) on pEGFP vector used for DBPII
expression on COS7 cells. COS7 cells transfected with different mutated DBPII
transgenes, were incubated on cover slips in 24 well plates for 42 hr (Chitnis &
Miller, 1994). The cells were then fixed with PBS/2% formaldehyde for 15 min,
washed with PBS and incubated at room temperature with 5 µg/ml of anti-DBPII
mAbs 3C9, 3D10 and 2D10 and anti-AMA1 mAb 1F9, as a negative control, for
90 min. After PBS wash, the cells were incubated with rhodamine-conjugated
goat anti-mouse secondary antibody (KPL) in PBS/0.1%BSA for 30 min in the
dark. The cells were washed with PBS and nuclear stain Hoechst at 1:1000
dilution for 15 mins in the dark. After the final wash, the cells on the coverslip was
fixed onto a glass slide with flurophoreG and stored at -20°C until ready to be
observed using a fluorescence microscope. Zeiss microscope was used to
capture images of 10 cells at 40X magnification for each DBPII-antibody pair at
constant exposure time of 88ms for blue channel, 513ms for green channel and
2049ms for red channel. Relative fluorescence unit (RFU) across a cell from end
to end was collected. The highest 50 points for the red channel for each cell was
used to normalize for the size of cells. The sum of the highest 50 points for 10
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cells was used to determine the mean RFU for each DBPII-antibody pair. The
mean RFU of DBPII mutants were compared with wild type DBPII Sal1 for the
respective antibody.

RESULTS
The phagemid vector pHENH6 was used to be express DBPII as a
chimera, fused with a C-terminal c-myc epitope tag and the pIII minor coat
protein on the surface of the engineered pHENH6 phage (Fig.2.1). The variable
length DBPII fragments came from a gene fragment library of random length
PvDBP coding constructed by DNAseI-digesting DNA encoding DBPII sequences
(Fig. 2.2 and 2.3). Recombinant phagemid libraries for Sal1 and 7.18 that were
estimated to have 7 x 105 pfu/µg and 4.6 x 106 pfu/µg of plasmid DNA gene
fragments. Sequencing of 40 random clones of each library revealed that the
fragments in the library spanned the entire coding sequence and no bias towards
any particular region was observed (Fig. 2.4); however, as expected most of the
fragments were ligated out of frame or in the incorrect orientation. Phage stocks
generated from the gene fragment libraries were biopanned on mAbs 3D10, 3C9,
2D10, 2C6 and 2H2 to enrich for high affinity binders to each of these antibodies.
Affinity selection of reactive phage to the target antibody was carried out
through the sequential rounds of panning by standard procedures. ELISAs were
carried out with positive control mAb 9E10 to standardize library titer in each
round of panning, while an anti-PfAMA1 antibody, mAb 1F9, served as a
negative control (Figs. 2.5 – 2.9 A and B). Panning on mAb 3D10 selected for
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phage clones that bound well to mAb 3D10, but poorly to mAbs 3C9 and 1F9 for
both gene fragment libraries (Fig. 2.5 A and B). In contrast, panning on mAb 3C9
selected for phage clones from both gene fragment libraries that bound well to
mAb 3C9 and poorly to mAbs 3D10 and 1F9 (Fig. 2.6 A and B). Likewise
panning on mAb 2D10 (Fig 2.7 A and B), mAb 2C6 (Fig 2.8 A and B) and mAb
2H2 (Fig 2.9 A and B) isolated phage clones that bound well to their respective
target antibody but bound poorly to mAbs 1F9 and 3D10 for both gene fragment
libraries. Phage clones isolated from panning on all the antibodies bound well to
mAb 9E10, suggesting that the procedure had enriched for clones possessing
DBPII coding sequence in-frame and in the correct-orientation.
Sequence analysis of 10 clones from each round of panning was used to
identify the length and specificity of DBPII CDS inserts. Clones from the last
rounds of panning tended to have inserts of similar sizes while those of the early
rounds tended to be more variable. Sequencing results further showed that only
clones in the last round of panning were in frame and in the right orientation,
corroborating ELISA results. Ten clones from the last rounds of panning on mAb
3D10, had overlapping fragments of sub-domain 1 of DBPII in-frame and in the
correct orientation (Fig. 2.5 C and D). Most clones from the last rounds of
panning on mAb 3C9 were comprised of overlapping fragments of sub-domain 3
(Fig. 2.6 C and D). However clones from the last rounds of panning on mAb
2D10 (Fig. 2.7 C and D), mAb 2C6 (Fig. 2.8 C and D) and mAb 2H2 (Fig. 2.9 C
and D) had a fragment that comprised of almost all of sub-domain 3.
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Phage were cultured from two clones enriched for during round 3 panning
on mAb 3D10 and three clones enriched for during round 3 panning on mAb
3C9. Each phage clone was tested for reactivity to the selecting mAb by ELISA
and Western Blot (Fig. 2.10). Results from both assays indicated that mAb 3D10
phage clones bound specifically to mAb 3D10 (Fig. 2.10 A and C). Similarly, mAb
3C9 phage clones were found to bind specifically to mAb 3C9 (Fig. 2.10 B and
D). The observed specificity suggested that the isolated phage clones displayed
the minimal fragments of DBPII needed for the mAbs to bind their respective
epitopes.
To further characterize the linear epitope for mAb 3D10, a random 20mer
peptide library termed Adlib1 (courtesy of Adalta Pty Ltd.) was also used to pan
on the antibody. After 3 rounds of biopanning using the approach outlined in
Figure 2.1 B, the level of reactivity enrichment was assessed by ELISA. Figure
2.11 shows that phage from rounds 1, 2 and 3 react well with mAb 3D10 (black)
and relatively poorly to the negative isotype control anti AMA1 mAb 5G8 (white).
Individual clones from round 3 were sequenced. From 10 clones, 4 sequences
were identified, each containing what may be a degenerate sequence motif
(highlighted in bold underline). An apparent key feature within the 3D10 epitope
is a hydrophilic 3-residue motif YK(R/Y/E). Although the Adlib1 peptide library is
unrelated to DBPII, YKR is present in the DBPII sequence in the 22 amino acid
region of sub-domain 1 that was selected for by the gene fragment library.
Further characterization to determine the potential immunogenicity of the
minimal epitopes was pursued next. The minimal peptides identified from
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panning with DBPII gene fragment libraries and the random peptide library were
produced synthetically and conjugated to KLH carrier protein to produce
immunize mice (Table 1). Following two boosts, ELISAs were carried out to
determine reactivity of the anti-peptide sera for the minimal peptide epitopes of
3D10 and 3C9. Serum from each mouse was tested for affinity to its
corresponding peptide. All peptides, with the exception of the 3D10 epitope
peptide, were immunogenic. Further, the serum from each mouse was tested for
affinity to rDBPII, by ELISA. Only mice immunized with 3C9 epitope peptide
produced an immune response that recognized rDBPII (Fig 2.13 A).
To assess anti-3C9 epitope peptide sera for its potential to inhibit DBPIIerythrocyte binding, a standard in vitro COS7 binding inhibition assay was carried
out (Fig 2.13 B). A concentration-dependent inhibition of binding of DBPIIerythrocytes was observed. Serum dilution that correspond to 50% inhibition
(IC50) of binding of erythrocytes to the DBPII alleles were 1:313.6 for Sal1,
1:309.1 for 7.18, 1:171.6 for AH and 1:52.73 for P. Binding inhibition curves of
each allele was compared to Sal1 using Dunnett’s multiple comparison test.
Alleles 7.18 and AH showed no significant difference compared to Sal1,
suggesting that 3C9-e1 produced and antibody response that recognizes a
conserved region of DBPII within these alleles.
Site directed mutagenesis was performed to substitute residues of the
epitopes that were identified through biopanning (Fig 2.14). These residues are
predicted to be surface exposed and reactive with the mAb. The purpose of this
procedure was to validate the relative importance each residue within the epitope
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may have in antibody binding. Immunofluorescence assay were performed to
determine the ability of the antibodies to bind to DBPII mutated at specific
residues expressed on the surface of COS7 cells. The relative fluorescence unit
(RFU) was used to compare binding of antibody to wild type DBPII Sal1 and
mutant.
Mutation of a single residue E538A (M20) within the 3C9 epitope
remarkably reduced binding of mAb 3C9 compared to DBPII Sal1 (Fig 2.15 A).
Mutant 6, Y445A/V446A/F530A/F535A (M6) also showed reduction in binding to
mAb 3C9. Structurally, residues E538 and F535, on the epitope, seem to interact
with residues Y445 upstream to the epitope but still in subdomain3 (Fig 2.16 A
and 2.17 C). It is interesting to note that the single mutation of F535 (Mutant 19)
had almost no difference in binding to mAb 3C9 compared to DBPII Sal1 and yet
this mutation greatly reduced binding to mAb 2D10 (Fig 2.15 B). A similar effect
is observed with the single amino acid substitution E529A (Mutant 14), which
greatly reduced binding to mAb 2D10 but no effect on mAb 3C9 binding.
Structurally, V446 seems to interact with G442 which when mutated also showed
reduction in binding (Mutant 4) to mAb 2D10 and not to mAb 3C9 (Fig 2.16 B and
2.17 D). Multiple mutations to residues Y445A, V446A, F530A and F535A
(Mutant 6) reduced binding to both mAb 3C9 and mAb 2D10.

DISCUSSION
Plasmodium vivax DBP is vital for merozoite invasion of Duffy positive
reticulocytes making it the foremost vaccine candidate against blood stage vivax
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malaria (Miller et al., 1976). PvDBP is a member of the Duffy-binding-like
erythrocyte binding proteins (DBL-EBPs) family (Adams et al., 1992) that
includes P. falciparum EBA175, PfEBL1, P. knowlesi DBPα,β and γ among
others (Adams et al., 2001). Studies of DBP have historically helped to define our
understanding of the important biological properties of this important family of
malaria parasite ligands. The N-terminal cysteine rich region is the ligand domain
known as the DBL domain or DBP region II in P. vivax that is essential of
receptor recognition (Adams et al., 1992; Chitnis & Miller, 1994). Intergenic
variation in this region is important for altering receptor specificity while intragenic
or allelic variation of the ligand domain alters antigenic character. DBP allelic
variation is mainly constrained to polymorphisms in the DBL domain and varies
by geographic region (Hwang, Kim, & Kho, 2009; Ju et al., 2012; Premaratne,
Aravinda, Escalante, & Udagama, 2011). Some polymorphic residues on DBPII
are unique to a certain geographical region while others are common among
global vivax alleles, like residues K371E, D384G, E385K, K386N, N417K, L424I,
W437R and I503K (Babaeekho, Zakeri, & Djadid, 2009; Hwang et al., 2009; Ju et
al., 2013; Ju et al., 2012). Generally, variation occurs in non essential residues
flanking residues critical for receptor recognition while variation in some residues
is more important than in others. For example, residues 417, 437 and 503 were
identified as critical determinants of antigenic character, since altering these
residues conferred a significant change in sensitivity to inhibitory anti-DBP
antibodies (VanBuskirk, Cole-Tobian, et al., 2004). Overall evidence indicates
that variation plays an important role in strain-specific immunity to DBP.
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DBPII is largely alpha-helical and may be assigned into three sub-domains
delineated by six disulphide bonds. While sub-domain1 of DBPII is made up of
an antiparallel beta-hairpin, sub-domains 2 and 3 are seen as distinct bundles of
three alpha-helixes (Batchelor et al., 2011).	
  	
  NMR studies of PvDBPII in contact
with the core region of DARC ectodomain revealed that dimerization of DBPII is
required for and driven by receptor engagement as DARC ectodomain form a
helix that binds to the dimer interface (Batchelor et al., 2014). Human anti-DBP
inhibitory antibodies have been shown to bind to sub-domain 2 in a surface
region adjacent to the dimer interface (Batchelor et al., 2014; Chootong et al.,
2010). Given that these dominant Bc epitopes are at the dimer interface are not
part of residues critical for either dimerization of receptor binding, anti-DBP
immune efficacy appears to be primarily mediated through steric hindrance of
dimerization.
Naturally acquired immunity to DBPII is present in P. vivax endemic areas,
anti-DBPII immune response tends to increase with age and exposure (Chootong
et al., 2010; J. L. Cole-Tobian et al., 2002; Grimberg et al., 2007; VanBuskirk,
Cole-Tobian, et al., 2004; Xainli et al., 2003). Studies have shown that about 810% of P. vivax-exposed individuals produce high titer strain-transcending or
broadly neutralizing antibodies (King et al., 2008), associated with 50% reduction
in risk of infection with P. vivax (Chootong et al., 2010; King et al., 2008).
Concurrently, the antibody responses to DBP seen in people living in P. vivax
endemic areas and the elevated levels of amino acid sequence polymorphisms
are consistent with the hypothesis that the molecule is under immune selective
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pressure, especially as the DBP polymorphisms are concentrated in the ligand
domain region II, which has a nucleotide substitution rate four times higher than
the rest of the molecule (Ampudia et al., 1996; J. L. Cole-Tobian et al., 2002;
Fraser et al., 1997; P. A. Michon et al., 1998; Tsuboi et al., 1994). In previous
studies we have identified epitopes reactive with polyclonal human immune
antibodies using an array of overlapping linear peptides attached to plastic pins.
This methodology proved to be surprisingly robust in identifying conformational
epitopes, especially the dominant Bc epitope. This epitope termed “DEK” for its
first three amino acids was confirmed subsequently to be a major target of
naturally occurring human immune antibodies and a major determinant for
controlling strain specific immunity elicited by vaccination (Ntumngia & Adams,
2012; Ntumngia et al., 2013). The current study sought to identify specific epitope
targets of mAbs induced by vaccination in mice, using phage display technology.
Phage display technology is a great tool for elucidating the molecular
nature of protein-protein interactions (Coley et al., 2001; Smith, 1985; Wilson &
Finlay, 1998) and we have established the methodology for DBPII. Recombinant
filamentous phage was engineered to display DBPII (Sal1 and 7.18 alleles) on its
surface as part of the pIII capsid protein. Selective panning of recombinant phage
libraries on antibodies was used to isolate target epitopes or peptide mimics.
Positive epitope-containing clones reactive with the anti-DBPII inhibitory
antibodies were enriched by successive panning assays. The sequence identity
of the selected peptides was determined by DNA sequencing. The identified
recombinant fragments and peptides represent epitope-specific reagents that
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were used to evaluate reactivity of epitope-specific antibodies. A surprising
outcome in this study is the discovery that Bc epitope targets of highly inhibitory
anti-DBP are located in subdomain III away from the dimer interface and
residues determined to be critical for erythrocyte binding. Only minimal epitope
target of an inhibitory antibody could be defined whereas the minimal target of
most inhibitory mAbs was the entire subdomain III (Fig 6, 7 and 8). In contrast
the minimal epitope of the non-inhibitory mAb 3D10 was located in a surface
region of subdomain I closer to the dimer interface.
Site directed mutagenesis studies revealed that binding inhibitory mAbs
3C9 and 2D10 are both sensitive to disruption of Y445, V446, F530 and F535
pocket present on the surface of sub-domain 3. Although F530 and F535 make
up part of the 3C9 epitope identified using phage displaying DBPII gene fragment
library, single amino acid mutation of these residues did not disrupt binding of
3C9. This suggests that there is some synergistic interaction of these aromatic
residues that make up the 3C9 and 2D10 binding pocket on DBPII. E538 seems
to have polar interactions with F535 in the epitope and Y445 in the neighboring
helix, which seems to be more important for binding of mAb 3C9 than mAb 2D10.
However, V446 seems to interact with G442, which is more important for binding
of mAb 2D10 than mAb 3C9.
The 3C9 minimal peptide epitope was further characterized by vaccination
studies to determine its potential as a subunit synthetic vaccine. The
immunogenicity of the ‘protective’ 3C9 epitope was compared to the minimal
peptide epitope of 3D10. Although 3D10 represented the highest titer mAb within
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the anti-DBP panel created, and was reacted equally to all DBP alleles tested by
ELISA, it has virtually no ability to block DBPII to erythrocytes (Ntumngia et al.,
2012a).
Various studies have examined the functional efficacy of vaccine-induced
anti-DBP antibodies to block DBP erythrocyte binding or inhibition of merozoite
invasion of erythrocyte (Arevalo-Herrera et al., 2005; Devi et al., 2007; Grimberg
et al., 2007; Ntumngia et al., 2013). As a general rule properly refolded
recombinant rDBPII that is capable of erythrocyte binding activity is required for
induction of inhibitory anti-DBPII antibodies. Indeed the epitope targets of the
protective mAb 3C9 (conformational) and non-protective mAb 3D10 (partially
linear) are consistent with this observation. In our approach the DBP peptide
immunogens, consisting of the synthetic linear peptides of the 3C9 or 3D10
epitopes were conjugated to carrier KLH, were used to immunize mice. The
3D10 immunogens included mimotope peptides of epitope targets isolated from a
random peptide library. Surprisingly, we found that a 3C9 epitope peptide
successfully induced an antibody response reactive to the immunizing peptide,
the refolded peptide as well as inhibitory to DBPII erythrocyte binding. This result
suggests that the 3C9 linear peptide has some inherent structural tendency to
assume its 3D conformation displayed on the surface of native DBP and is the
target of inhibitory antibody. Peptides like 3C9 epitope peptide, capable of
eliciting protective antibodies, may be critical for the design of a sub-unit vaccine
against asexual blood stage vivax malaria.
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Figure 2.1: Schematic of the different components of phage display system and
biopanning for epitope mapping
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Figure 2.2: Schematic of the construction of DBPII gene fragment library
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Figure 2.3: DNA gels of pHEN-H6 vector and insert DBPII Sal1 and 7.18
digested to make up gene fragment library. (A) pHEN-H6 vector seen in lane 2
was digested with PstI restriction enzyme seen in lane 3 (B) Small scale digest of
DBPII Sal1 with DNAseI was carried out to determine DNAseI concentration to
obtain the most broad spread of fragments. (C) Lane 3 shows DBPII Sal1 and
lane 4 shows DBPII Sal1 DNAseI digested (D) Lane 2 shows DBPII 7.18 and
lane 3 shows DBPII 7.18 DNAseI digested. The digested vector and gene
fragments were blunt-ended with Vent polymerase and ligated before being
electroporated into TG1 E. coli.
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Figure 2.4: Schematic of sequences generated from DBPII Sal1 & 7.18 gene
fragment libraries. Sequencing of PCR products generated by screening 40
individual clones revealed that the gene fragments in the library spanned the
entire coding sequence, with no bias towards any particular region. The different
colours represent the lengths of the various gene fragments generated.
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Figure 2.5: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning
on mAb 3D10. ELISA showing reactivity of phage clones enriched by successive
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII
7.18. A pool of phage from each round of panning was tested for binding to antiDBPII mAbs 3D10, 3C9 and the anti-c-myc epitope tag antibody mAb-9E10. The
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars
represent mean OD of triplicate wells and error bars indicate ±SD. Individual
clones (n=10) from the last round of panning with each of the libraries were PCR
amplified and sequenced. The positions of the various peptides identified are
indicated in (C) and (D) for mAbs 3D10. The degenerate sequence identified
from the phage clones by panning on each on the antibodies is shown.
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Figure 2.6: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning
on mAb 3C9. ELISA showing reactivity of phage clones enriched by successive
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII
7.18. A pool of phage from each round of panning was tested for binding to antiDBPII mAbs 3C9, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. The
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars
represent mean OD of triplicate wells and error bars indicate ±SD. Individual
clones (n=10) from the last round of panning with each of the libraries were PCR
amplified and sequenced. The positions of the various peptides identified are
indicated in (C) and (D) for mAbs 3C9. The degenerate sequence identified from
the phage clones by panning on each on the antibodies is shown.
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Figure 2.7: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning
on mAb 2D10. ELISA showing reactivity of phage clones enriched by successive
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII
7.18. A pool of phage from each round of panning was tested for binding to antiDBPII mAbs 2D10, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10.
The PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars
represent mean OD of triplicate wells and error bars indicate ±SD. Individual
clones (n=10) from the last round of panning with each of the libraries were PCR
amplified and sequenced. The positions of the various peptides identified are
indicated in (C) and (D) for mAbs 2D10.
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Figure 2.8: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning
on mAb 2C6. ELISA showing reactivity of phage clones enriched by successive
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII
7.18. A pool of phage from each round of panning was tested for binding to antiDBPII mAbs 2C6, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. The
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars
represent mean OD of triplicate wells and error bars indicate ±SD. Individual
clones (n=10) from the last round of panning with each of the libraries were PCR
amplified and sequenced. The positions of the various peptides identified are
indicated in (C) and (D) for mAbs 2C6.
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Figure 2.9: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning
on mAb 2H2. ELISA showing reactivity of phage clones enriched by successive
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII
7.18. A pool of phage from each round of panning was tested for binding to antiDBPII mAbs 2H2, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. The
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars
represent mean OD of triplicate wells and error bars indicate ±SD. Individual
clones (n=10) from the last round of panning with each of the libraries were PCR
amplified and sequenced. The positions of the various peptides identified are
indicated in (C) and (D) for mAbs 2H2.
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Figure 2.10: Specificity of isolated phage clones with mAb-3D10 and 3C9. Phage
clones identified from round 3 biopanning on mAb 3D10 (C4 and C5) and mAb
3C9 (C4, C6, C9) as well as phage clones expressing sub-domain 1 (sd1) and
sub-domain 3 (sd3) fragments of DBPII were tested for cross reactivity with the
homologous and heterologous antibodies by ELISA (A and B) and immunoblot
analysis (C and D). mAb-3D10 binds specifically to clones C4 and C5 and the
sd1 expressing clones, while mAb-3C9 binds only to mAb-3C9 isolated clones
and sd3 expressing clones. mAb-1F9 is a non-specific anti-DBPII antibody used
as negative control and mAb-9E10 is specific to the c-myc epitope of the
phagemid. Each bar represents the mean OD450 of triplicate wells and error bars
represent ±SD.

	
  

70

A"

1.2"

OD"450"nm"

1"
0.8"
0.6"

mAb$3D10)
mAb$5G8)

0.4"
0.2"
0"
R1"

R2"

R3"

No"phage"

Pos"C"

Rounds"of"panning"

B"

I I N H A F L Q N T V M K N C N Y K R K R R!
V G N L D F S R F H K S S L D Y K R G Q!
V K F T D R Y K Y S S M K G Y A R Q G R
!
K I N M Y K E V R T R Q L S V R P S P E

DBPII!
M1!
!! M2!
M3! !

!

!

Figure 2.11: Panning a random peptide on mAb-3D10. (a) ELISA showing
reactivity of phage clones from rounds of panning on mAb-3D10. mAb-5G8
served as a negative control antibody, while a mAb-5G8 positive binding phage
clone (Pos C) served as a positive control. The bars represent mean of triplicate
wells while the error bars represent ±SD. (b) Alignment of a sequence of the
mAb-3D10 binding epitope on sd1 of DBPII (top) and sequences of three
mimotopes (M1, M2 and M3) from random peptide library with affinity for mAb3D10. the underlined residues show a three amino acid motif common to the
DBPII epitope and the sequences from the mimotopes isolated form the random
peptide library.
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Figure 2.12: Putative epitopes of mAbs 3C9 and 3D10. Crystal structure of DBPII
dimer with sub-domains 1 (in green), 2 (in tan) and 3 (in light blue). Putative
epitope of inhibitory mAb 3C9 (in red) is on sub-domain 3 while putative epitope
of non-inhibitory mAb 3D10 (in navy blue) is on sub-domain 1. The two views
represent the front and back of the ligand for the surface model (top) and for
secondary structure cartoon (bottom).

Table 2.1: Peptides identified through biopanning used for immunizations.

Name
3C9$e1
3D10$e2
3D10$m1
3D10$m2
3D10$m3
Control

Peptide+Sequence
DILKQELDEFNEVAFENE
IINHAFLQNTVMKNCNYKRKRR
VGNLDFSRFHKSSLDYKRGQ
VKFTDRYKYSSMKGYARQGR
KINMYKEVRTRQLSVRPSPE
TPDERYRELDSHAQNESC

ELISA+with+
Peptide
rDBPII+Sal1
+
+
+
1
+
1
+
1
+
1
+
1

Peptides were conjugated to KLH and used to immunize groups of ten BALB/c
mice. Following two boosts sera was collected. Sera was tested for antibodies to
corresponding peptides and to rDBPII Sal1 by ELISA.
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Figure 2.13: Anti 3C9-e1 sera characterization. (A) Mice immunized with 3C9-e1
produced an antibody response that recognized rDBPII by ELISA. The numbers
for each curve correspond to sera from a mouse. Each point on the curve
represent mean OD of triplicate wells and error bars indicate ±SD. (B) Pooled
group sera was used to test for erythrocyte-DBPII binding inhibition by in vitro
COS7 assay. The curves correspond to the different alleles of DBPII that were
tested. Each point on the curve represent percent inhibition of two experiments
each with triplicate wells and error bars indicate ±SD.
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Figure 2.14: Amino acid sequence alignment of DBPII Sal1 to mutants. Site
directed mutagenesis of DBPII Sal1 with alanine substitutions at specific sites
depicted in red.
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Figure 2.15: Immunofluorescent assay of DBPII mutants expressed on COS7
cells. Fluorescence images of 10 cells for each DBPII-antibody pair was
captured. Mean pixel intensity for each DBPII-antibody pair was determined.
Each bar represents mean pixel intensity compared to DBPII Sal1 and error bars
indicate ±SD.
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Figure 2.16: Crystallographic representation of residues on DBPII important for
antibody binding. (A) Residues important for binding to mAb 3C9, in red single
substitution of mutant 20 and in blue multiple substitutions of mutant 6. (B)
Residues important for binding to mAb 2D10, in blue multiple substitutions of
mutant 6, in red single substitution of mutant 19 (also a part of mutant 6), single
substitution of mutant 4 and 14 in green and purple.
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Figure 2.17: Crystallographic representation of putative mAbs 3C9 and 2D10
binding sites on DBPII. (A) Cartoon representation of DBPII monomer in yellow
and 3C9 epitope in blue. (B) Cartoon representation of 3C9 epitope with residue
side chains as line representation. (C) Polar interactions in green that seem
important for mAb 3C9 binding. (D) Polar interactions in green that seem
important for mAb 2D10 binding.
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CHAPTER THREE:
RANDOMIZED HELICAL SCAFFOLD AFFIBODY LIBRARY TO MAP
CONFORMATIONAL EPITOPES ON PLASMODIUM VIVAX DUFFY BINDING
PROTEIN

ABSTRACT
Plasmodium vivax Duffy binding protein (DBP) is an essential ligand for
reticulocyte invasion making it a premier asexual blood stage vaccine candidate.
However, as DBP is highly polymorphic in its ligand domain and prone to elicit an
immune response that is strain specific. Vaccine design studies have mapped Bc
epitope targets of inhibitory and non-inhibitory antibodies to characterize
conserved epitopes that could be used to over come the challenges of allelic
variation. Since DBP region II is mostly made up of alpha-helices, we used a
randomized helical scaffold library, the Affibody library, displayed on M13 phage,
to determine conformational epitopes. Affibody libraries, an engineered affinity
protein scaffold have been previously used to select for high affinity binders to
receptors or enzymes. The novelty of this study is in the use of this randomized
helical scaffold library to display conformational epitopes.

INTRODUCTION
Plasmodium vivax has the widest geographical distribution and is the
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second most prevalent of the five Plasmodium species that cause malaria in
humans ("World Malaria Report 2014," 2014). Although historically called ‘benign
tertian malaria’ because it is less virulent than P. falciparum (Garnham, 1951),
when trying to eliminate malaria, P. vivax is often the ‘last parasite standing’
(Tatem et al., 2010), Complicating elimination of vivax malaria is the added
obstacle of reactivation or relapse of active blood-stage infections from dormant
liver stages, referred to as hypnozoites, that occurs several weeks to years after
the first infection by bite of a mosquito (Krotoski, 1985). Clearance of these
dormant liver stages requires the use of the 8-aminoquinoline drug primaquine
because most drugs effective against blood-stages of P. vivax have no effect on
hypnozoites More recently there have also been a rise in the number of severe
cases of vivax malaria (Alexandre et al., 2010; Kochar et al., 2009), widespread
drug resistance (Baird, Basri, et al., 1991; Price et al., 2014; Rieckmann et al.,
1989) including strains with low sensitivity to primaquine (Baird & Hoffman,
2004). There is an urgent need to develop a vaccine to control and prevent vivax
malaria.
Naturally acquired immunity to malaria is largely associated with antibody
response to blood stage infection, specifically against proteins involved in the
invasion of erythrocytes (Marsh & Kinyanjui, 2006; Yazdani et al., 2006).
Consistent with this view, many of the parasite antigens considered as targets of
this protective immunity display the characteristic patterns of polymorphisms of
residues under selective immune pressure. Duffy binding protein is a prime
example of such blood-stage target, exhibiting extensive variation in residues of
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its functional ligand domain. Plasmodium vivax almost exclusively invades Duffy
positive red blood cells, although recently there have been a few unexplained
sporadic cases of vivax among Duffy negative individuals (Cavasini et al., 2007;
Menard et al., 2013; Ryan et al., 2006). The exclusivity of P. vivax is attributed to
the Duffy binding protein on the merozoite which binds irreversibly to its cognate
receptor, the Duffy antigen receptor for chemokines (DARC), on the erythrocyte,
forming the junction critical for invasion (Adams et al., 1990; Adams et al., 1992;
Chitnis et al., 1996; Miller et al., 1976; Miller et al., 1975; Wertheimer & Barnwell,
1989). Hence DBP region II (DBPII), essential for binding to DARC (Chitnis &
Miller, 1994; Ranjan & Chitnis, 1999; VanBuskirk, Sevova, et al., 2004), is a
prime asexual blood stage vaccine candidate.
As a result of the highly polymorphic nature of DBPII (Ampudia et al.,
1996; Tsuboi et al., 1994; Xainli et al., 2000), naturally acquired immunity is
strain specific (J. L. Cole-Tobian et al., 2009; McHenry et al., 2011; Ntumngia et
al., 2012b; VanBuskirk, Cole-Tobian, et al., 2004). In pre-clinical mouse studies,
a multi-allele DBPII vaccine was more immunogenic and produced a stronger
strain neutralizing response than a single-allele vaccine (Ntumngia et al., 2013).
To over come the inherent strain specificity of the immune response to DBPII, a
novel synthetic DBPII antigen called DEKnull, was designed. This was derived by
mutating the residues of an immunodominant polymorphic B-cell epitope within
DBPII, referred to as the “DEK” epitope. Compared to its natural parent allele
Sal1, DEKnull vaccine was less immunogenic but produced an immune response
that was similar to a single natural allele vaccine (Ntumngia & Adams, 2012;
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Ntumngia et al., 2013), suggesting that the immune response was to one or more
conserved epitopes. These studies prove that identifying epitopes on DBPII will
be very helpful in designing a vaccine that produces strain-transcending
immunity.
Almost since the discovery of phage display as a tool, epitope mapping
studies have been conducted to help design a vaccine against malaria (de la
Cruz, Lal, & McCutchan, 1988; Parmley & Smith, 1989). Although an epitope
may only be a few residues, many epitopes are composed of discontinuous
residues that come together to create a 3D conformation-dependent epitope of
the protein that is crucial for optimal antibody binding, rendering gene fragment
libraries and random peptide libraries less than ideal to elucidate all critical
residues that make up an epitope. Nonetheless as demonstrated by the studies
presented in Chapter 2 it is possible for even linear synthetic peptides to induce
some level of inhibition to a native protein dependent on its 3D structure for
function. Therefore, providing some additional structural support via a protein
scaffold for presentation of DBPII epitopes may enhance immunogenicity and
functional efficacy of vaccine-elicited antibodies to inhibit DBP function.
Non-immunoglobulin affinity protein scaffolds is a growing field marked
with varied polypeptide folds that are highly stable, easily produced and dotted
with various residue positions that can be randomized. One type of helical
scaffold library, Affibodies, engineered from Staphylococcal protein A (Fig 3.1), is
similar to Monobodies, a bête scaffold engineered from human fibronectin.
Affibodies have been used to select for receptors or enzymes with affinities
	
  

87

(dissociation constant KD) in the 10µM to 3nM range (Gunneriusson et al., 1999;
Hansson et al., 1999; Nord et al., 1997; Nord et al., 2001). Here we propose that
these protein scaffold libraries could also be used to identify conformational
epitopes reactive with inhibitory anti-DBPII mAbs.
Crystallography studies reveal that DBPII is largely alpha-helical and may be
assigned into three sub-domains delineated by six disulphide bonds (Batchelor et
al., 2011). While sub-domain 1 of DBPII is made up of an antiparallel betahairpin, sub-domains 2 and 3 are seen as distinct bundles of three alpha-helixes.
Inhibitory human and murine mAbs have been shown to bind to sub-domain 2
(Chootong et al., 2010) and sub-domain 3 (presented in Chapter 2), respectively.
This study has sought to use an alternate alphahelical scaffold as a tool for
isolation of DBPII structural epitopes. An affibody library (Nord et al., 1997),
representing a randomized, three alpha-helical bundle structure, was used to
screen for conformation-dependent epitope mimics reactive with the murine antiDBPII mAbs. The purpose of the study was to determine if a rigid scaffold, such
as the Affibody, could provide an alternate phage system for identifying and
characterizing mimotopes of DBPII.

MATERIALS AND METHODS
Biotinylation of antibodies
Murine mAbs 3D10, 3C9, 2D10 and 1DK of IgG isotype IgG1 and κ light
chain were used. Biotinylation of target mAbs 3D10, 3C9 and 2D10 were carried
	
  

88

out using N-Hydroxysuccinimide (NHS) activated biotin with EZ-Link Sulfo-NHSLC-Biotin (Thermo Scientific 21327) following manufacturer’s instructions at 20
molar fold excess biotin followed by dialysis. The level of biotinylation was
determined by evaluation of binding to streptavidin-coated beads as seen on a
10% SDS PAGE gel. Monoclonal antibody 1DK was left unbiotinylated and was
used as a control.

Affiibody selections
The Affibody library (naïve library pAffi100-tryp designed by PÅ 2013) on
the phagemid vector pKN1 (Nord, Nilsson, Nilsson, Uhlen, & Nygren, 1995) was
grown in E. coli strain RR1ΔM15 (supE) (Ruther, 1982). Phage stocks were
prepared using M13K07 helper phage. Washed neutravidin magnetic particles
(Spherotech NVM-20-5) and Streptavidin beads (Invitrogen Dynabeads M-280)
were incubated with excess biotinylated target mAbs for 1 h at room temperature
with end-over-end rotation. The beads were then washed and stored at 4°C to be
used alternatively through the round of panning. The panning procedure was
carried out as described previously (Hansson et al., 1999; Nord et al., 1997) over
four rounds with an increasing number of PBST (PBS with 0.05% Tween 20)
washes (2, 5 and 6 more washes). Briefly, Affibody library of approximately 1011
phage forming units in 500 µl was first subjected to negative pre-selection by
incubation with neutravidin magnetic particles, 100 nM mAb1DK and 3% BSA for
1 h on a rotator at room temperature. Unbound phage particles were then
transferred for selection to target mAb on neutravidin magnetic particles, by
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incubating on a rotator for 1 h at room temperature and then washed with PBST.
Bound phage particles were eluted for 10 min with 500 µl of Glycine HCl, pH 2.7
and immediately neutralized with 50 µl of TrisHCl, pH 9. The eluted phage was
used to infect log phase RR1ΔM15 E. coli grown in 100 ml of Tryptic Soy Broth
supplemented with 20% Glucose for 1 h at 37°C. Helper phage was added and
incubated for 30 min at 37°C. The cells were pelleted and resuspended in 100 ml
Tryptic Soy Broth Yeast Extract media containing with 0.1M IPTG, 100 µg/ml
Ampicillin and 25 µg/ml Kanamycin, grown over night at 30°C with shaking.
Phage particles were isolated using standard polyethylene glycol precipitation
and the concentration was determined for the subsequent round of selection.

ELISA screen of clones
Phage clones from the eluate of round four panning were randomly picked
and grown in 1 ml of Tryptic Soy Broth Yeast Extract media with 0.1M IPTG and
100 µg/ml Ampicillin for 24 h at 30°C with shaking. Affibody present in the
periplasmic membrane was extracted in PBST by repeated freeze-thaw cycles.
ELISA plates were coated with 5 µg/ml of human serum albumin over night at
4°C. PBST wash was followed by incubation of 100 µl of periplasmic content
from each clone for 2 h at room temperature. Unbound periplasmic content was
then washed off with PBST and 5 µg/ml of the primary mAb in 0.5% casein or 1%
milk in PBST was added and incubated for 1 h at room temperature. This was
followed by addition of secondary goat anti-mouse horseradish peroxidase
conjugated antibody at 1:5000 dilution. Absorbance was read at 450nm.
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Sequencing
Colonies from round 4 of panning that produced a strong response by
ELISA was sequenced. Colony PCR was carried out using primers 5’CACACAGGAAACAGCTATGACCAT-3’ and 5’CTATCAGTGCTTTTACACCTTCAACAG-3’. The PCR product was purified by
ethanol precipitation and sequenced using BigDye Terminators 3.1 (Applied
Biosystems) with cycle sequencing DNA methodology on a MegaBACETM 1000
instrument (Amersham Biosciences).

RESULTS
Anti-DBPII murine mAbs 3C9, 2D10 and 3D10 were biotinylated and then
affinity selected on neutravidin and streptavidin beads (Fig 3.2). As a control, a
biotinylated human IgG mAbs was also allowed to bind to both kinds of beads. All
mAbs bound well to each of the beads and excess is seen in the supernatant,
suggesting that the beads were saturated. Gels show two distinct bands for the
heavy chain and the light chain. A third bovine serum albumin (BSA) band is
seen in wells loaded with streptavidin beads as these beads were stored with
BSA (Fig 3.2 B). These purified avidin conjugated-mAbs were used to capture
phage displayed affibodies that have an affinity to the mAb.
After four rounds of panning of the Affibody library on each monoclonal
antibody we analyzed individual clones. Periplasmic extract from 96 clones from
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round four for each mAb panned on, were screened for affinity to the target mAb
and another mAb as a control for background (Fig 3.3). In order to account for
non-specific binding, only clones that showed greater affinity to the target mAb
(in black) compared to the control mAb (in gray) were considered for sequencing.
Conformation-independent mAb 3D10 (Fig 3.3 A) has fewer clones that bound
with affinity compared to conformation dependent mAb 3C9 (Fig 3.3 B) and mAb
2D10 (Fig 3.3 C). DNA sequencing results form clones identified show that there
are few clones that have picked up variant residues at the central Isoleucine 31
residue (Fig 3.4, 3.5 and 3.6).

DISCUSSION
The DBPII is primarily composed of alpha-helices with an antiparallel betahairpin near the N-terminus (Batchelor et al., 2011). This elongate boomerang
shaped structure can be further divided into sub-domains delineated by
disulphide bonds. Human inhibitory mAb epitopes have been mapped to the
three helix bundle structure of sub-domain 2 (Chootong et al., 2010) while
inhibitory murine mAbs bind to sub-domain 3 (presented in chapter 2) which is
also made up of a three helix bundle. As a proof of concept experiment, the use
of helical scaffold Affibody library to identify epitopes of murine mAbs that vary in
both binding inhibition of DBPII-erythrocyte and conformation dependents of
DBPII. Similar anti-idiotypic studies on HIV-1 Env-specific antibodies were
carried out using the 10th domain of human fibronectin (FNfn10) as an
engineered scaffold to generate Monobodies that mimicked both linear epitopes

	
  

92

(mAbs 2F5 and 4E10) and conformational epitopes (b12 and VRCO1) (Sullivan
et al., 2013).
Staphylococcal protein A is widely used in antibody purification and
detection (Uhlen, Forsberg, Moks, Hartmanis, & Nilsson, 1992). Protein A has
repetitive structures consisting of small individually folded, highly stable alphahelical domains that specifically binds to the Fc region of IgG from different
species (Moks et al., 1986; Samuelsson, Jonasson, Viklund, Nilsson, & Uhlen,
1996; Samuelsson, Moks, Nilsson, & Uhlen, 1994; Stahl & Nygren, 1997). The
58-residue B domain, engineered with a single amino acid mutation for increased
chemical stability (Protein Z), was further determined to be tolerant to multiple
random amino acid substitutions at the Fc binding surface (Cedergren,
Andersson, Jansson, Uhlen, & Nilsson, 1993; Jendeberg et al., 1995; Nilsson et
al., 1987; Nord et al., 1995) giving rise to the Z domain libraries (Nord et al.,
1997) later to be called Affibodies library (Hansson et al., 1999). Using M13
phage these libraries could be displayed as a fusion protein and be used for
affinity selection or biopanning (Nord et al., 1995). This combinatorial library was
first randomized at 13 residues distributed across helix 1 and 2 (Fig 3.1). Initially
it was thought that Isoleucine at position 31 on helix 2 is important for helix-helix
packing and was not included as a residue to be randomized. However, it was
later determined that because of its central position on the randomized region,
substitution of this residue may provide useful information about binding sites
that may use a variant residue at the central position of Ile31.
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Selection of Affibodies showing anti-idiotypic characteristic has been well
established (Eklund, Axelsson, Uhlen, & Nygren, 2002). Crystal structure of a
complex of an in vitro selected Affibody bound to protein Z reveals similar
properties to antibody-antigen complex (Hogbom, Eklund, Nygren, & Nordlund,
2003). This study of an artificially evolved protein –protein complex of two
globular proteins is similar to Ab-antigen complex marked by the complex burring
at 1,665 Å2 and the nine H bonds. However the rigidity of the three helix structure
compared to the loops that form the complementary determining region of Abs
and the lack of a buried water molecule in the Affibody complex, suggests that
the interaction is more complementary than the typical Ab-antigen complexes.
Hence these studies show that the Affibody can form a complex with a protein
similar to that of an antibody, interacting with similar residues, and that the
Affibody – protein complex can be selected for in vitro. We use these findings as
the bases to study the interaction of anti-DBP antibodies to the helical structure
of DBPII using the Affibody library.
Conformation dependent anti DBPII mAbs 3C9 (IC50 = 0.19 and 0.16
µg/ml) and 2D10 (0.35 and 0.18 µg/ml) showed differential inhibitory responses
to the DBPII alleles 7.18 and Sal1, respectively, expressed on COS7 cells
(Ntumngia et al., 2012b). This suggests that either these antibodies might be
binding to different epitopes within the different alleles or that the polymorphisms
in DBPII sub-domain 3 has significant influence on functional activity of these
antibodies. While both mAbs 2D10 and 3C9 were produced in mice immunized
with DBPII 7.18 allele, 2D10 showed almost 2 fold increase in inhibition
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compared to Sal1 allele. Conformation independent non-inhibitory mAb 3D10
binds to recombinant refolded DBPII with significantly greater affinity (~5 fold)
than denatured rDBPII.
The Affibody library used in this study not only had the original 13
randomized residues, on helix 1 and 2, involved in the Fc-binding activity but also
Ile31 was randomized to include Asp, His, Lys and Tyr, each at 10%, at position
31. It is interesting to note that several of the Affibody clones that bound well to
the target antibody had one of these substitutes for Isoleucine at position 31.
Amino acid sequence alignment of 3C9 epitope on DBPII (presented in Chapter
2) along with round 4 clones from panning on mAb 3C9 suggests that a good
portion of non-randomized region of the Affibody helix is conserved in the 3C9
epitope. Hence making it increasingly difficult to identify residues of importance.
MAb 2D10 also seems to bind a region very close to the 3C9 epitope on DBPII
(presented in Chapter 2) and clones from round 4 panning also align well to the
C terminal region of DBPII subdomain3.
Competition ELISAs and site directed mutagenesis studies need to be
carried out to determine essential residues. More in-depth structural alignment
studies of DBPII and Affibody clones that were identified may be required to draw
conclusions on the residues that are most essential for the mAbs 3C9 and mAb
2D10. Another round of panning may also help identify clones that bind with
affinity affinities KD in the µM to nM range to determine essential residues that
make up the helical structure of the epitope.
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TABLES AND FIGURES

Figure 3.1: Affibody crystal structure and sequence. Crystal structure of an
Affibody (pdb1h0t) with randomized regions shown as sticks in peach and Ile31
in green (Wahlberg et al., 2003).
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Figure 3.2: SDS-PAGE gel of biotinylated antibodies on neutravidin and
streptavidin beads. Biotinylated antibodies incubated with Neutravidin beads (A)
and streptavidin beads (B) were run on 10% reducing gel as antibody bound
beads (b) and supernatant (s) along with protein ladder (L). Distinct bands for
heavy (<66kDa) and light chains (30kDa) can be seen on both gels. A third BSA
band (66kDa) is seen in wells with streptavidin beads as BSA was in the storage
buffer.
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Figure 3.3: ELISA on clones from Round 4 panning on murine mAbs. Affibody
from periplasmic content of clones from the last round of panning were tested for
affinity to its respective antibody as well as a control antibody. Clones that
showed higher binding to mAb 3D10 (in A), mAb 3C9 (in B) and mAb 2D10 (in C)
compared to the control antibody were studied further.
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Figure 3.4: Amino acid sequence alignments for Round 4 panning on mAb 3C9.
Clones from round 4 were aligned to 3C9 epitope on DBPII. Highlighted in gray
are the amino acid residues that were conserved in the Affibody helix.
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Figure 3.5: Amino acid sequence alignments for Round 4 panning on mAb 2D10.
Clones from round 4 were aligned. Highlighted in gray are the amino acid
residues that were conserved in the Affibody helix.

Figure 3.6: Amino acid sequence alignments for Round 4 panning on mAb 3D10.
Clones from round 4 were aligned. Highlighted in gray are the amino acid
residues that were conserved in the Affibody helix.
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CHAPTER FOUR:
SUMMARY

Malaria causes a huge burden of disease globally, with about 3.3 billion people at
risk of being infected ("World Malaria Report 2014," 2014). Plasmodium vivax is
the second most common cause of human malaria. Plasmodium vivax
preferentially invades reticulocytes (Butcher et al., 1973; Mons, 1990) with Duffy
blood group antigen otherwise known as Duffy antigen receptor for chemokines
(DARC) (Miller et al., 1976). Plasmodium vivax Duffy binding protein (DBP),
expressed on the merozoite surface just in time for invasion, binds to its cognate
receptor DARC on the reticulocyte surface forming an irreversible junction,
critical for merozoite invasion (Adams et al., 1990; Adams et al., 1992; Chitnis et
al., 1996; Miller et al., 1976; Miller et al., 1975; Wertheimer & Barnwell, 1989).
Plasmodium vivax almost exclusively use DARC as a receptor to invade
reticulocytes, however, more recently, there have been a few P. vivax cases
reported among Duffy negative individuals (Cavasini et al., 2007; Menard et al.,
2013; Ryan et al., 2006), this is rare and an alternate receptor-ligand invasion
pathway is unknown. Hence PvDBP remains a prime candidate for vaccineinduced immunity against asexual blood stage P. vivax infection.
The cysteine rich DBP region II (DBPII) that constitutes the principal
determinants for receptor recognition (Adams et al., 1992; Chitnis & Miller, 1994;
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Ranjan & Chitnis, 1999; VanBuskirk, Sevova, et al., 2004) is highly polymorphic
(Ampudia et al., 1996; Tsuboi et al., 1994; Xainli et al., 2000), in a pattern
consistent with high immune selection pressure on DBPII (Baum et al., 2003;
Baum et al., 2002). Residues critical for receptor recognition are flanked by
polymorphic residues that are not important for binding to the receptor (Batchelor
et al., 2011; VanBuskirk, Sevova, et al., 2004; Xainli et al., 2000). These
polymorphisms are a challenge to developing a vaccine since they contribute to
anti-DBP strain-specific in naturally acquired immunity (J. L. Cole-Tobian et al.,
2009; McHenry et al., 2011; Ntumngia et al., 2012b; VanBuskirk, Cole-Tobian, et
al., 2004).
To overcome the inherent tendency for anti-DBP immune responses to be
strain specific, a novel synthetic DBPII called DEKnull was produced. The B-cell
immunodominat and polymorphic residues of the DEK epitope (Chootong et al.,
2010) were mutated in DEKnull. Compared to the natural parent allele Sal1,
DEKnull vaccine was less immunogenic but it produced an immune response, in
mice, that was similar to a single natural allele vaccine (Ntumngia & Adams,
2012; Ntumngia et al., 2013). These studies prove that identifying conserved
protective epitopes on DBP will be very helpful in designing a vaccine that
produces a broadly neutralizing, strain-transcending immunity.
Previously, we generated and immunologically characterized a panel of
anti-DBPII murine mAbs. Some of these mAbs were broadly inhibitory like mAbs
3C9, 2D10, 2C6 and 2H2 while mAb 3D10 was a poor inhibitor to DBPIIerythrocyte binding in a standard in vitro COS 7 cell assay (Ntumngia et al.,
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2012b). With the exception of mAb 3D10, all the mAbs specifically recognized
only conformational dependent epitopes on recombinant DBPII.
Phage display has been a useful tool for epitope mapping with the
advantages of rapidly producing refolded protein, fused to phage coat; forming a
traceable link back to the genotype (Smith, 1985; Wilson & Finlay, 1998).
Crystallography studies reveal that DBPII is largely alpha-helical and may be
assigned into three sub-domains delineated by six disulphide bonds (Batchelor et
al., 2011). Using phage display we have previously shown that, each of the subdomains or natural combinations of the sub-domains of DBPII have varying
patterns of affinity to these mAbs (Siddiqui et al., 2012). These data suggest that
identifying the epitopes of these inhibitory and non-inhibitory mAbs will help
design a strain-transcending subunit vaccine.
In this study, we further map the epitopes of these anti-DBPII mAbs by
screening DBPII (Sal1 and 7.18) gene fragment libraries using phage display.
After three to four rounds of affinity selection to each of the mAbs, DNA
sequence from bacterial clones of the last round the minimal reactive peptide
fragments were identified. Interestingly, a region on subdomain 3 was the epitope
on DBPII for broadly inhibitory mAbs 3C9, 2D10, 2C6 and 2H2 while noninhibitory mAb 3D10 epitope was on subdomain 1.
Further, panning using a random peptide library or a random scaffold
library and site directed mutagenesis was used to determine the relative
importance of residues within the identified epitope region. Panning using a
random 20-mer peptide library to define the minimal epitope of conformation
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independent mAb 3D10 identified the ‘YKR’ region common between the DPBII
epitope and round 3 mimotopes. A random scaffold library was also used to
study the epitopes of conformation dependent mAbs 3C9 and 2D10. Further
analysis of structural and amino acid sequence alignments needs to be carried
out.
Site directed mutagenesis studies reveled that multiple mutations to
residues Y445A, V446A, F530A and F535A reduced binding to both mAb 3C9
and mAb 2D10 suggesting that there is some synergistic interaction of these
aromatic residues that make up the 3C9 and 2D10 binding pocket on. E538
seems to have polar interactions with F535 in the epitope and Y445 in the
neighboring helix, which seems to be more important for binding of mAb 3C9
than mAb 2D10. However, V446 seems to interact with G442, which is more
important for binding of mAb 2D10 than mAb 3C9.
Peptides identified from the gene fragment library panning and random
peptide panning were conjugated to carrier protein KLH and used to immunize
mice. All groups of mice produced an immune response to the respective
peptide, determined by ELISA. However, only 3C9 epitope peptide elicited
antibodies that recognized rDBPII. Using the standard in vitro COS7 assay a
concentration-dependent inhibition of DBPII-erythrocyte binding was observed
using anti-3C9 epitope sera. Binding inhibition curves for alleles 7.18 and AH
showed no significant difference compared to Sal1. These results show promise
that the 3C9 linear peptide may be inherently able to assume its 3D conformation
as on native DBP and it is a target of binding inhibitory antibody.
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These results from this study contribute to our understanding of the
specific targets for vaccine-elicited protective immunity. In particular, this study
demonstrates an approach that may be successful in boosting antibody
responses targeted against conserved protective epitopes, with functional
inhibition against broader allelic variants and diverse P. vivax strains.
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Miriam George <miriamtgeorge@gmail.com>

ID: 178588 Permission authorization for WHO copyrighted material
permissions@who.int <permissions@who.int>
To: miriamtgeorge@gmail.com
Cc: permissions@who.int

22 July 2015 at 18:45

Dear Ms George
Thank you for your request for permission to reprint and reproduce certain WHO copyrighted material .
On behalf of the World Health Organization, we are pleased to authorize your request to reproduce the WHO
materials as detailed in the form below, subject to the terms and conditions of the non-exclusive licence below.
If you have questions regarding this authorization, please contact permissions@who.int.
We thank you for your interest in WHO published materials.
Kind regards,
WHO Permissions team

WORLD HEALTH ORGANIZATION (WHO)

Non-exclusive licence to use selected WHO published materials
You submitted a request, through WHO’s online platform, for permission to reprint and reproduce certain WHO
copyrighted material (the "Licensed Materials"). This is a legal agreement (the "Agreement") between you and
WHO, granting you a licence to use the Licensed Materials subject to the terms and conditions herein.
Read this Agreement in its entirety before using the Licensed Materials.

By using the Licensed Materials, you enter into, and agree to be bound by, this Agreement.
This licence is granted only for original materials belonging to WHO. If any part of the WHO published
materials you wish to reproduce are credited by WHO to a source other than WHO, those materials are not
covered by this Agreement and are not part of the Licensed Materials. You are responsible for
determining if this is the case, and if so, you are responsible for obtaining any necessary permission from
the source of those third-party materials prior to their use.
If you enter into this Agreement on behalf of an organization, by using the Licensed Materials you confirm
(represent and warrant) that you are authorized by your organization to enter into this Agreement on the
organization’s behalf. In such a case, the terms "you" and "your" in this Agreement refer to, and this Agreement
applies to, the organization.
WHO grants this license to you based on the representations and warranties you made in the license
request you submitted through WHO’s online platform. If any of those representations and/or warranties
are or become false or inaccurate, this license agreement shall automatically terminate with immediate
effect, without prejudice to any other remedies which WHO may have.
https://mail.google.com/mail/u/0/?ui=2&ik=b87c036b94&view=pt&search=inbox&msg=14eb7f15e93c3550&siml=14eb7f15e93c3550
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If you have questions regarding this Agreement, please contact permissions@who.int.
1. Licence. Subject to the terms and Conditions of this Agreement, WHO grants to you a worldwide, royalty free,
non-transferable, non-sublicensable, non-exclusive licence to use, reproduce, publish, and display the Licensed
Materials in the manner and using the media indicated in the Permissions Request Form you submitted to WHO
(the "Licensed Use"). This licence is limited to the current edition of your publication. Future editions or a different
use of the Licensed Materials will require additional permission from WHO. If your request includes translation into
different languages, then non-exclusive permission is hereby granted to translate the Licensed Materials into the
languages indicated.
2. Retained Rights. Copyright in the Licensed Materials remains vested in WHO, and WHO retains all rights not
specifically granted under this Agreement.
3. Mandatory Acknowledgement. In every instance of the Licensed Use, you must make suitable
acknowledgement of WHO, either as a footnote or in a reference list at the end of your publication, as follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No.,
Copyright (Year)."

In addition, If the Licensed Materials originate from the WHO web site, you must also include the URL reference
and the date accessed.
Translations of the Licensed Materials should be attributed as follows:
"Translated with permission of the publisher from Publication title, Vol /edition number, Author(s), Title of
article / title of chapter, Pages No., Year."

4. Altering or Modifying the Licensed Materials. As part of the Licensed Use, you may minimally alter or adapt
figures and tables in the Licensed Materials to match the style of your publication. Any other alteration or
modification of the Licensed Materials (including abbreviations, additions, or deletions) may be made only with the
prior written authorization of WHO.
5. Appropriate and Prohibited Uses. You must use the Licensed Materials in a factual and appropriate context.
You may not use the Licensed Materials in association with any product marketing, promotional, or commercial
activities, including, without limitation, in advertisements, product brochures, company-sponsored web sites,
annual reports, or other non-educational publications or distributions.
6. No WHO endorsement. You shall not state or imply that WHO endorses or is affiliated with your publication or
the Licensed Use, or that WHO endorses any entity, organization, company, or product.
7. No use of the WHO logo. In no case shall you use the WHO name or emblem, or any abbreviation thereof.
Notwithstanding the foregoing, if the WHO name and/or emblem appear as an integral part of the Licensed
Materials (e.g. on a map) you may use the name and/or emblem in your use of the License Materials, provided the
name and/or logo is not used separately from the Licensed Materials.
8. No Warranties by WHO. All reasonable precautions have been taken by WHO to verify the information
contained in the Licensed Materials. However, WHO provides the Licensed Materials to you without warranty of
any kind, either expressed or implied, and you are entirely responsible for your use of the Licensed Materials. In
no event shall WHO be liable for damages arising from your use of the Licensed Materials.
9. Your Indemnification of WHO. You agree to indemnify WHO for, and hold WHO harmless against, any claim for
damages, losses, and/or any costs, including attorneys' fees, arising in any manner whatsoever from your use of
the Licensed Materials or for your breach of any of the terms of this Agreement.
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10. Termination. The licence and the rights granted under this Agreement shall terminate automatically upon any
breach by you of the terms of this Agreement. Further, WHO may terminate this licence at any time with
immediate effect for any reason by written notice to you.
11. Entire Agreement, Amendment. This Agreement is the entire agreement between you and WHO with respect
to its subject matter. WHO is not bound by any additional terms that may appear in any communication from you.
This Agreement may only be amended by mutual written agreement of you and WHO.
12. Headings. Paragraph headings in this Agreement are for reference only.
13. Dispute resolution. Any dispute relating to the interpretation or application of this Agreement shall, unless
amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by
arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties
or, in the absence of agreement, with the rules of arbitration of the International Chamber of Commerce. The
parties shall accept the arbitral award as final.
14. Privileges and immunities. Nothing in or relating to this Agreement shall be deemed a waiver of any of the
privileges and immunities enjoyed by WHO under national or international law and/or as submitting WHO to any
national court jurisdiction.
***

DataCol Web: Form to request permission to reproduce or reprint WHO copyrighted material
===================================================
ID: 178588
Section: Contact details
--------------------------------------------------* Title
* Ms
------------------------* First name
* Miriam
------------------------* Family name
* George
------------------------* Organization/affiliation
* University of South Florida
------------------------* Web site address
*
------------------------* Type of organization
* University/Academic
------------------------* If other, please specify
*
------------------------* Position
*
------------------------* Telephone
* +1-813-965-8930
------------------------* Address
* 3720 Spectrum Blvd, Sute 304
------------------------https://mail.google.com/mail/u/0/?ui=2&ik=b87c036b94&view=pt&search=inbox&msg=14eb7f15e93c3550&siml=14eb7f15e93c3550
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* Country
* United States of America
------------------------* Email
* miriamtgeorge@gmail.com
Section: Information about WHO material to be reproduced
--------------------------------------------------* Full title of WHO material from which the reproduction is to be made
* World Malaria Report 2014
------------------------* Website URL where WHO material is published
* http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/
------------------------* ISBN / WHO Reference Number
* 978 92 4 156483 0/WHO/HTM/GMP/2015.2
------------------------* Please select the item(s) to be reproduced
* Figure
------------------------* Type of reuse
* Dissertation/thesis
------------------------* No of item(s) to be reproduced
* 5 items or less
------------------------* For each item, please provide a reference and page number. If entire document, please state "Entire document".
* Figure 1.1 Countries with ongoing transmission of malaria, 2013 on Page no. 2
Section: Information about your publication
--------------------------------------------------* Please provide the title of your publication that the above materials are to be published in
* Immunological Characterization Of Duffy Binding Protein Of Plasmodium vivax
------------------------* Publishing format
* PDF
------------------------* Will you be translating?
* No
------------------------* If yes, please indicate languages
*
------------------------* If web please provide URL / If other, please specify
* http://scholarcommons.usf.edu
------------------------* Number of copies (if applicable)
*5
------------------------* Target audience and planned distribution
* Students
------------------------* Planned publication/distribution date
* Aug 2016
------------------------* If your publication or the material is to be sold, indicate the planned selling price or subscription fee
*0
------------------------* Is your publication sponsored or funded by an organisation other than your own?
* No
------------------------https://mail.google.com/mail/u/0/?ui=2&ik=b87c036b94&view=pt&search=inbox&msg=14eb7f15e93c3550&siml=14eb7f15e93c3550
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* If yes, please provide additional information
*
------------------------* Will there be any advertising associated with your publication?
* No
------------------------* If yes, please provide additional information
*
------------------------* Subject(s) of interest that most correspond to your request
* Malaria
------------------------* Additional information about your request
* Like most US universities do, the dissertation will be made available online at Scholar commons and at
ProQuest. Please advice on the most appropriate mode of action. I greatly appreciate your assistance.
------------------------* Approval
* Auto permission
------------------------* Latest approval modification
------------------------* WHO Department
* ACP, ACT
Section: Terms and conditions
--------------------------------------------------* By submitting this request you confirm that you will abide by the terms and conditions if WHO grants you
permission.
* I have read and agree with the terms and conditions
--------------------------------------------------Click the following link to access a format view of this record:
http://apps.who.int/datacol/survey.asp?survey_id=258&respondent_id=178588
--------------------------------------------------This email was automatically sent to you by the WHO Intranet Data Collector.
The DataCol can send emails to accounts specified by the Form focalpoint.
---------------------------------------------------
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JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Jul 27, 2015

This Agreement between Miriam T George ("You") and John Wiley and Sons ("John Wiley
and Sons") consists of your license details and the terms and conditions provided by John
Wiley and Sons and Copyright Clearance Center.
License Number

3675580332780

License date

Jul 24, 2015

Licensed Content Publisher

John Wiley and Sons

Licensed Content Publication Journal of Internal Medicine
Licensed Content Title

The path of malaria vaccine development: challenges and
perspectives

Licensed Content Author

C. Arama,M. Troye-Blomberg

Licensed Content Date

Apr 18, 2014

Pages

11

Type of use

I don't see my intended use

Is the reuse sponsored by or None
associated with a
pharmaceutical or medical
products company?
Special requirements

As a part of my dissertation and would like to request permission to
use one figure in the article, figure 1-The life cycle of Plasmodium
falciparum. Like most US universities, the dissertation will be made
available online at Scholar commons and at ProQuest. This will be
used for non-commercial purposes and will not be translated or
adapted. Please advice on the most appropriate mode of action. I
appreciate your assistance.

Requestor Location

Miriam T George
3720 Spectrum Blvd
Sute 304
TAMPA, FL 33612
United States
Attn: Miriam T George

Billing Type

Invoice

Billing Address

Miriam T George
18705 Planners Way
LUTZ, FL 33548
United States
Attn: Miriam T George

Total

0.00 USD

Terms and Conditions

TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a"Wiley Company") or handled on behalf of a society with
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which a Wiley Company has exclusive publishing rights in relation to a particular work
(collectively "WILEY"). By clicking accept in connection with completing this licensing
transaction, you agree that the following terms and conditions apply to this transaction
(along with the billing and payment terms and conditions established by the Copyright
Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that
you opened your Rightslink account (these are available at any time at
http://myaccount.copyright.com).
Terms and Conditions
• The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.
• You are hereby granted a personal, non-exclusive, non-sub licensable (on a standalone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license is for a onetime use only and limited to any maximum distribution number specified in the
license. The first instance of republication or reuse granted by this licence must be
completed within two years of the date of the grant of this licence (although copies
prepared before the end date may be distributed thereafter). The Wiley Materials shall
not be used in any other manner or for any other purpose, beyond what is granted in
the license. Permission is granted subject to an appropriate acknowledgement given to
the author, title of the material/book/journal and the publisher. You shall also
duplicate the copyright notice that appears in the Wiley publication in your use of the
Wiley Material. Permission is also granted on the understanding that nowhere in the
text is a previously published source acknowledged for all or part of this Wiley
Material. Any third party content is expressly excluded from this permission.
• With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner. You may not alter, remove or suppress
in any manner any copyright, trademark or other notices displayed by the Wiley
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security,
transfer or assign the Wiley Materials on a stand-alone basis, or any of the rights
granted to you hereunder to any other person.
• The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto.
• NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
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EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU
• WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
• You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
• IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
• Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby.
• The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party.
• This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
• Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
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• These terms and conditions together with CCC s Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns.
• In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC s Billing and Payment terms and
conditions, these terms and conditions shall prevail.
• WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC s Billing and Payment
terms and conditions.
• This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
• This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state s conflict of law rules.
Any legal action, suit or proceeding arising out of or relating to these Terms and
Conditions or the breach thereof shall be instituted in a court of competent jurisdiction
in New York County in the State of New York in the United States of America and
each party hereby consents and submits to the personal jurisdiction of such court,
waives any objection to venue in such court and consents to service of process by
registered or certified mail, return receipt requested, at the last known address of such
party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses:: Creative Commons Attribution (CC-BY) license Creative
Commons Attribution Non-Commercial (CC-BY-NC) license and Creative Commons
Attribution Non-Commercial-NoDerivs (CC-BY-NC-ND) License. The license type is
clearly identified on the article.
Copyright in any research article in a journal published as Open Access under a Creative
Commons License is retained by the author(s). Authors grant Wiley a license to publish the
article and identify itself as the original publisher. Authors also grant any third party the
right to use the article freely as long as its integrity is maintained and its original authors,
citation details and publisher are identified as follows: [Title of Article/Author/Journal Title
and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the Journal]. Links
to the final article on Wiley s website are encouraged where applicable.
The Creative Commons Attribution License
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The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-commercial re-use of an open access article, as long as
the author is properly attributed.
The Creative Commons Attribution License does not affect the moral rights of authors,
including without limitation the right not to have their work subjected to derogatory
treatment. It also does not affect any other rights held by authors or third parties in the
article, including without limitation the rights of privacy and publicity. Use of the article
must not assert or imply, whether implicitly or explicitly, any connection with, endorsement
or sponsorship of such use by the author, publisher or any other party associated with the
article.
For any reuse or distribution, users must include the copyright notice and make clear to
others that the article is made available under a Creative Commons Attribution license,
linking to the relevant Creative Commons web page.
To the fullest extent permitted by applicable law, the article is made available as is and
without representation or warranties of any kind whether express, implied, statutory or
otherwise and including, without limitation, warranties of title, merchantability, fitness for a
particular purpose, non-infringement, absence of defects, accuracy, or the presence or
absence of errors.
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC) License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by non-commercial users
For non-commercial and non-promotional purposes, individual users may access, download,
copy, display and redistribute to colleagues Wiley Open Access articles, as well as adapt,
translate, text- and data-mine the content subject to the following conditions:
• The authors' moral rights are not compromised. These rights include the right of
"paternity" (also known as "attribution" - the right for the author to be identified as
such) and "integrity" (the right for the author not to have the work altered in such a
way that the author's reputation or integrity may be impugned).
• Where content in the article is identified as belonging to a third party, it is the
obligation of the user to ensure that any reuse complies with the copyright policies of
the owner of that content.
• If article content is copied, downloaded or otherwise reused for non-commercial
research and education purposes, a link to the appropriate bibliographic citation
(authors, journal, article title, volume, issue, page numbers, DOI and the link to the
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definitive published version on Wiley Online Library) should be maintained.
Copyright notices and disclaimers must not be deleted.
• Any translations, for which a prior translation agreement with Wiley has not been
agreed, must prominently display the statement: "This is an unofficial translation of an
article that appeared in a Wiley publication. The publisher has not endorsed this
translation."
Use by commercial "for-profit" organisations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee. Commercial
purposes include:
• Copying or downloading of articles, or linking to such articles for further
redistribution, sale or licensing;
• Copying, downloading or posting by a site or service that incorporates advertising
with such content;
• The inclusion or incorporation of article content in other works or services (other than
normal quotations with an appropriate citation) that is then available for sale or
licensing, for a fee (for example, a compilation produced for marketing purposes,
inclusion in a sales pack)
• Use of article content (other than normal quotations with appropriate citation) by forprofit organisations for promotional purposes
• Linking to article content in e-mails redistributed for promotional, marketing or
educational purposes;
• Use for the purposes of monetary reward by means of sale, resale, licence, loan,
transfer or other form of commercial exploitation such as marketing products
• Print reprints of Wiley Open Access articles can be purchased from:
corporatesales@wiley.com
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html

Other Terms and Conditions:

v1.9
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authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
Confirmation (and/or any invoice) and payment by User of the full amount set forth on that

	
  

125

https://s100.copyright.com/CustomerAdmin/PrintableLicenseFrame.jsp?ref=255f3cc7... 2015-07-27

Rightslink Printable License

Page 3 of 5

document includes only those rights expressly set forth in the Order Confirmation and in
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notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
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8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
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User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
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8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
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Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
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8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
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of New York, USA, or in any federal or state court whose geographical jurisdiction covers
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To:

George, Miriam;

Permission is granted for your use of the figure as described in your message. Please cite the PNAS article in
full, and include "Copyright (2004) National Academy of Sciences, U.S.A." as a copyright note. Because this
material published between 1993 and 2008, a copyright note is needed. Let us know if you have any questions.
Best regards,
Kay McLaughlin for
Diane Sullenberger
Executive Editor
PNAS
From: George, Miriam [mailto:mgeorge@health.usf.edu]
Sent: Wednesday, July 22, 2015 6:05 PM
To: PNAS Permissions
Subject: Request to use one figure for dissertation

Hi
!
As a part of my dissertation and would like to request permission to use one figure in the
article VanBuskirk, K. M., Sevova, E., & Adams, J. H. (2004). Conserved residues in the
Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor
recognition. Proc Natl Acad Sci U S A, 101(44), 15754-15759. doi: 0405421101 [pii]
10.1073/pnas.0405421101, figure-1: Schematic drawing of the important structural
domains of the DBP. page no.-15755
Like most US universities do, the dissertation will be made available online at Scholar
commons and at ProQuest. Please advice on the most appropriate mode of action. I
greatly appreciate your assistance.
!
Thank you
!
Miriam George
PhD Candidate
Dept Global Health
University of South Florida
Ph: 813-965-8930
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1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of this
material. However, you should ensure that the material you are requesting is original to
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indicates that it was reprinted or adapted by NPG with permission from another source,
then you should also seek permission from that source to reuse the material.
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3. Permission granted for a first edition does not apply to second and subsequent editions and
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or where the first edition permission was granted for free).
4. Nature Publishing Group's permission must be acknowledged next to the figure, table or
abstract in print. In electronic form, this acknowledgement must be visible at the same
time as the figure/table/abstract, and must be hyperlinked to the journal's homepage.
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Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] (reference
citation), copyright (year of publication)
Note: For adaptation from the British Journal of Cancer, the following credit line
applies.
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citation), copyright (year of publication).
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